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A B S T R A C T
Against a backdrop of global antibiotic resistance and increasing awareness of the importance of the human
microbiota, there has been resurgent interest in the potential use of bacteriophages for therapeutic purposes,
known as phage therapy. A number of phage therapy phase I and II clinical trials have concluded, and shown
phages don't present signiﬁcant adverse safety concerns. These clinical trials used simple phage suspensions
without any formulation and phage stability was of secondary concern. Phages have a limited stability in so-
lution, and undergo a signiﬁcant drop in phage titre during processing and storage which is unacceptable if
phages are to become regulated pharmaceuticals, where stable dosage and well deﬁned pharmacokinetics and
pharmacodynamics are de rigueur. Animal studies have shown that the eﬃcacy of phage therapy outcomes
depend on the phage concentration (i.e. the dose) delivered at the site of infection, and their ability to target and
kill bacteria, arresting bacterial growth and clearing the infection. In addition, in vitro and animal studies have
shown the importance of using phage cocktails rather than single phage preparations to achieve better therapy
outcomes. The in vivo reduction of phage concentration due to interactions with host antibodies or other
clearance mechanisms may necessitate repeated dosing of phages, or sustained release approaches. Modelling of
phage-bacterium population dynamics reinforces these points. Surprisingly little attention has been devoted to
the eﬀect of formulation on phage therapy outcomes, given the need for phage cocktails, where each phage
within a cocktail may require signiﬁcantly diﬀerent formulation to retain a high enough infective dose.
This review ﬁrstly looks at the clinical needs and challenges (informed through a review of key animal studies
evaluating phage therapy) associated with treatment of acute and chronic infections and the drivers for phage
encapsulation. An important driver for formulation and encapsulation is shelf life and storage of phage to ensure
reproducible dosages. Other drivers include formulation of phage for encapsulation in micro- and nanoparticles
for eﬀective delivery, encapsulation in stimuli responsive systems for triggered controlled or sustained release at
the targeted site of infection. Encapsulation of phage (e.g. in liposomes) may also be used to increase the cir-
culation time of phage for treating systemic infections, for prophylactic treatment or to treat intracellular in-
fections. We then proceed to document approaches used in the published literature on the formulation and
stabilisation of phage for storage and encapsulation of bacteriophage in micro- and nanostructured materials
using freeze drying (lyophilization), spray drying, in emulsions e.g. ointments, polymeric microparticles, na-
noparticles and liposomes. As phage therapy moves forward towards Phase III clinical trials, the review con-
cludes by looking at promising new approaches for micro- and nanoencapsulation of phages and how these may
address gaps in the ﬁeld.
1. Introduction
The discovery of antibiotics and the subsequent control of bacterial
infections may be regarded as a signiﬁcant achievement of modern
medicine. Surgery, transplantation and chemotherapy rely heavily on
the control of bacterial infections. Broad spectrum antibiotics are highly
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attractive since they may be used against a wide range of bacteria
without the need to identify the infection causing bacterial agent. This
advantage has also resulted in signiﬁcant misuse and overuse of anti-
biotics contributing to the emergence of antibiotic resistance [1]. Bac-
terial resistance to antibiotics has become a signiﬁcant problem in the
treatment of a wide range of infections where the bacteria commonly
causing the infections have become highly resistant to many classes of
antibiotics including third generation cephalosporins, carbapenems and
ﬂuoroquinolones [2]. Recent evidence of plasmid mediated colistin
resistance in Enterobacteriaceae is particularly troubling [3]. Between
1940 and 1962> 20 new classes of antibiotics came to market; since
then the antibiotic pipeline has produced only two new classes [4].
Coates et al. [4] estimate that to stem the rising tide of antibiotic re-
sistance 20 new classes of antibiotics are urgently needed. It is highly
unlikely that this goal will be achievable even if governments provided
stronger economic incentives to industry to develop new broad spec-
trum antibiotics. Czaplewski et al. [5] call for a sustained, concerted
and coordinated international eﬀort and discuss the need to invest in
the development of alternatives to antibiotics (non-compound ap-
proaches) including probiotics, vaccines as well bacteriophage and
phage derived lysins.
2. Bacteriophage as novel antimicrobials
Bacteriophages (viruses that infect bacteria) are highly abundant in
the environment and may be the source of low cost antimicrobials. The
focus of recent phage therapy approaches is on the use of lytic tailed
phages all of which belong to the Caudovirales and include the
Myoviridae, Siphoviridae and Podoviridae families [6]. Members of the
Caudovirales have an icosahedral capsid head that contains double-
stranded DNA (15–500 kbp), and a tail with surface receptor proteins
that interact with surface features on the host bacterium [7]. Successful
phage therapy requires interaction between the phage and the bac-
terium resulting in adsorption of the phage to the host bacterium fol-
lowed by injection of the phage DNA. The pharmacodynamics of this
process has been modelled using mathematical models based on col-
loidal interactions [8–10]. Upon infection, the phage replication cycle
ensues culminating (after a short latency period) in cell lysis and the
liberation of multiple phage virions (with a burst size that is typically
between 10 and 100 [11]). Gill and Hyman [12] and Weber-Dabrowska
et al. [13] provide an overview of key considerations related to phage
choice, isolation and puriﬁcation for phage therapy. Phage therapy
practice relies on the isolation of naturally occurring phage abundantly
found in the environment [14]. Typically, phage are isolated from the
environment and screened against commonly occurring pathogenic
bacterial strains (to identify host ranges) and then evaluated using in
vitro and in vivo animal models. The limitation of host ranges is
overcome through the use of phage cocktails to ensure suﬃcient cov-
erage of commonly occurring strains and the use of phage mixtures
targeting diﬀerent receptors reduces the probability of encountering
phage resistant bacterial mutants. Phages are generally manufactured
using standard fermentation process technology. In brief, host bacteria
are grown in liquid culture in a bioreactor. During the log growth
phase, phages are added to the bioreactor to infect the bacteria. In-
cubation of phage with bacteria results in phage adsorption to the
bacteria, infection and following a short lag period, release of bacter-
iophage virions. The resulting lysate contains the product (the ampli-
ﬁed phage) along with bacterial debris and residual fermentation
media. Removal of cellular debris is typically done using centrifugation
and/or ﬁltration. Ion exchange, gel ﬁltration etc. can be used to further
purify the bacteriophage (e.g. for the removal of host cell proteins, host
cell DNA or endotoxin for Gram negative bacteria). Typically phage
may then be re-suspended in simple saline or buﬀer and stored under
refrigerated conditions or processed further e.g. spray dried to improve
storage shelf life or encapsulated in micro- or nanoparticle formula-
tions.
Phage are unique antimicrobials in that in the presence of host
bacteria, they are able to increase their numbers by infecting the bac-
teria and producing virion progeny whilst minimally aﬀecting the
overall microbiota and body tissues. Phage carrying polysaccharide
depolymerases (polysaccharide degrading enzymes) in their structure
may be able to disrupt bioﬁlms [15–17]. For example Enterococcus and
Staphylococcus phage capable of destroying bioﬁlms have been reported
[18,19]. In addition to their potential as human biotherapeutics, phage
are being developed for agricultural use to rid the environment and
domestic animals of pathogens that could contaminate the food supply
chain [20], in aquaculture for the treatment of ﬁsh pathogens [21] and
for the control of infections in intensively farmed poultry [22,23]. Re-
cent advances in molecular biology and sequencing technology have
improved our basic understanding of how bacteriophage interact with
bacteria and have opened new possibilities for utilising phage, in-
cluding genetically engineered phage, for potential therapeutic and
diagnostic applications [7,24].
3. Phage therapy for acute and chronic infections
Most of the recent phage therapy studies (using small vertebrate
animals) have investigated treatments focusing on acute infections
(Table 1). In acute infections the speciﬁc infection causing bacterium
may be identiﬁed using suitable rapid diagnostic methods (e.g. lateral
ﬂow assays, PCR, MALDI-TOF Mass Spectrometry). In such instances,
narrow spectrum antimicrobials such as bacteriophages may provide a
suitable therapeutic alternative where organisms are resistant to
frontline antibiotics or to reduce the use of broad spectrum antibiotics
as part of a global eﬀort towards antibiotic stewardship. An example of
this is in cases of urinary tract infections where a signiﬁcant proportion
of the cases are caused by a particular pathotype Escherichia coli with
speciﬁc virulence factors [25]. Animal studies have shown that phage
may be eﬀective in certain instances e.g. in treating acute respiratory
infections caused by Pseudomonas aeruginosa [26–28] and in the treat-
ment of systemic infections caused by S. aureus [29]. A signiﬁcant focus
of phage therapy studies in animals has been around respiratory in-
fections, gastrointestinal infections and infections of the skin and
wounds (Table 1). Phage therapy studies with animals has shown that
in certain instances, it may help in reducing the densities of the in-
fecting bacterial populations to levels that may allow the host immune
response to mount a successful defence and clear the infection
[26,27,30].
A number of in vivo phage studies (with animals and humans) have
suggested that phage therapy may be beneﬁcial in the treatment of
diﬃcult to treat antibiotic resistant pulmonary infections (e.g. cystic
ﬁbrosis [26] and pneumonia [31,32]), topical and wound infections
[33,34] and gastrointestinal infections [35].
3.1. Challenges of antibiotic resistance for respiratory infections
Cystic ﬁbrosis (CF) is a genetic disease of the lung resulting in re-
duced hydration and thickening of secretions covering the respiratory
epithelium. Highly viscous mucus is not cleared by the epithelial cells
and eventually leads to chronic inﬂammation and bacterial infections.
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Two common bacterial strains isolated from sputum are Staphylococcus
aureus and Haemophilus inﬂuenzae, which are also one of the ﬁrst to
infect the lungs during childhood [36]. S. aureus can generally be
controlled with antibiotics but infection usually predisposes chronic
colonization. The main pathogen infecting the pulmonary epithelium is
Pseudomonas aeruginosa, which grows in bioﬁlms within the CF lungs
[37]. Several pulmonary pathogens are capable of forming bioﬁlms in
which the bacteria are encased in exopolysaccharide (EPS) and are less
metabolically active [38]. The extracellular matrix in the bioﬁlm im-
pairs the action of antibiotics acting as a diﬀusional barrier. The low
metabolic activity of the bacteria in the bioﬁlm also limits the eﬃcacy
of many classes of antibiotics that target various metabolic pathways.
Some bacteriophage may be able to degrade bioﬁlms and infect bacteria
residing within them [39,40]. Burkholderia cenocepacia are opportu-
nistic pathogens in CF causing acute pulmonary disease and sepsis or
chronic infection characterised by accelerated decline in lung function.
Multidrug resistant phenotypes are exhibited by most strains. There is a
need for alternative therapies to treat B. cenocepacia; several virulent
phages for B. cenocepacia have been characterised. A number of in vivo
phage therapy studies have looked at P. aeruginosa [26,27,28,41] and B.
cenocepacia [42] infections in animal models.
Ventilator-associated-pneumonia (VAP) occurs often in patients in
an intensive care unit setting. A clear respiratory airway is a necessity
for patient survival; after being intubated and receiving mechanical
ventilation, patients suﬀer from pneumonia caused by infection with P.
aeruginosa, S. aureus, Streptococcus pneumoniae, H. inﬂuenzae and
Acinetobacter baumannii which take advantage of the weakened immune
system of the patient. One of the major problems is antibiotic re-
sistance. Klebsiella sp., Enterobacter sp., Serrati sp., and Burkholderia sp.,
have also been reported as infecting bacteria. Klebsiella pneumoniae is an
opportunistic bacterial pathogen responsible for much community-ac-
quired pneumonia and a signiﬁcant proportion of hospital-acquired
pneumonia [31]. It is a leading cause of pneumonia morbidity and
mortality with resistance to carbapenems and other antibiotics [43]. A
number of in vivo phage therapy studies have looked at B. cepacia [42]
and K. pneumonia [31,32] infections in animal models.
Tuberculosis (TB) is a global health problem; one-third of the
world's population is infected with Mycobacterium tuberculosis (Mtb),
the agent of TB, and at risk of developing disease and transmitting in-
fection. Annually there are over 10 million new cases of TB and an
estimated 1.4 million deaths [44]. Multidrug resistant tuberculosis
cases are a signiﬁcant healthcare problem with extensively drug re-
sistant M. tuberculosis practically untreatable in low-income countries
[45]. Multi-drug resistant (MDR) Mtb strains are resistant to isoniazid
and rifampicin, two of the frontline antibiotics used to treat TB. The
World Health Organisation (WHO) estimate there were nearly 500,000
new cases of MDR TB in 2015 [44]. Most alarming are the development
of extensively drug resistant (XDR) strains, which are additionally re-
sistant to second line antibiotics. Although antibiotic treatment rapidly
reduces the infectiousness of patients, those with drug-resistant infec-
tions remain infectious during therapy until the drug resistance is
identiﬁed and the treatment regimen is changed. Treatment for TB is
protracted, requiring antibiotics to be taken for at least 6 months, rising
to two years for MDR infections. The antibiotics can have undesirable
side eﬀects, and interruptions to therapy (intermittent supply or patient
non-compliance) provide the opportunity for the development of drug
resistance and treatment failure. There is therefore, an urgent need for
new therapies to treat TB and also to shorten the length of treatment.
The Mtb bacillus is transmitted in aerosol droplets and therapies which
reduce patient infectiousness or prevent the establishment of new
infections will also have great impact on TB control. Infection is es-
tablished in a new host when inhaled Mtb bacilli in the lower re-
spiratory tract are engulfed by alveolar macrophages [46]. The bacilli
resist usual macrophage killing mechanisms and replicate, until such
time that the immune response triggers recruitment of systemic
mononuclear cells which surround the focus of infection and form a
granuloma. The centre of the granuloma becomes hypoxic, pH drops
and conditions no longer support bacterial growth. Instead the Mtb
bacilli remain in a dormant state with low metabolic activity, until such
time that the immune system weakens, the granuloma breaks down and
with this the bacilli reactivate and replicate once more. During this
active TB disease the patient excretes large number of bacilli when they
cough and can transmit the infection to new susceptible hosts. A
number of recent studies have started looking at phage therapy for the
treatment of TB infections [47,48] and strategies to tackle the challenge
of phage delivery to these intracellular bacteria.
3.2. Challenges of antibiotic resistance for wounds
Chronic wounds are a severe worldwide problem. A recent pre-
valence study estimated 2.2 million wounds managed by the UK
National Health Service (NHS) in 2012/2013 costing the UK NHS £5.3
billion [49]. Studies suggest that wound management accounts for over
half of community health nurse resources in European settings [50].
The majority of chronic wounds are colonized with bacteria that form
bioﬁlms, thereby compromising wound healing by making them more
refractory to treatment and slow tissue repair by stimulating chronic
inﬂammation at the wound site [51]. Antimicrobials including anti-
biotics and antiseptics are used clinically to decrease the bacterial load
and promote wound healing [52]. However, systemic antibiotic therapy
may be of little beneﬁt due to poor diﬀusion of antimicrobials through
the bioﬁlm and the poor eﬃcacy of antibiotics against bacteria with
reduced metabolic activity. This reduced activity increases antibiotic
tolerance since many classes of antibiotics are only eﬀective against
actively dividing bacteria by targeting peptidoglycan produced in the
cell wall (β-lactams), protein (aminoglycoside) synthesis, or DNA re-
plication (quinolones) [53]. Polymicrobial bioﬁlms in chronic wounds
are recognised as an important factor in the failure to achieve wound
healing in a timely fashion. As an example, diabetic foot infections
(DFI) typically tend to be polymicrobial with aerobic Gram-positive
cocci, especially staphylococci, the most common causative micro-
organism [54]. S. aureus and P. aeruginosa are considered important
pathogens in antibiotic resistant wound infections. A number of animal
studies have looked at phage therapy for treating S. aureus and P. aer-
uginosa wound infections [33,34].
3.3. Challenges of antibiotic resistance for gastrointestinal infections
Enteric pathogens form a large part of the healthcare burden around
the globe. The most common infection causing bacteria are Clostridium
diﬃcile causing C. diﬃcile associated diarrhoea [55], Shigella dysenteriae
causing shigellosis [56], Escherichia coli causing gastroenteritis [57],
Vibrio cholerae causing cholera [58], Salmonella enterica causing sal-
monellosis [59], Listeria monocytogenes causing listeriosis [60] and
Helicobacter pylori causing chronic gastritis [61]. The primary route of
infection in low income countries is through the faecal-oral route or
from contaminated food and water [62]. Treatment usually involves
antibiotics however, with emerging antibiotic resistance, infections
with antibiotic resistant organisms is on the rise, hence the need for
alternative therapy options. In addition to humans, these enteric
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pathogens are also capable of infecting farm animals resulting in high
antibiotic use for animal husbandry, emerging resistance and risk of
contamination of the food chain. Numerous studies have evaluated the
potential of phage therapy for the treatment of gastrointestinal infec-
tions caused by E. coli, S. enterica, V. cholera and C. diﬃcile (Table 1).
3.4. Phage-bacterium population dynamics - the need for bacteriophage
encapsulation
There are a number of speciﬁc features regarding phage-bacterium
dynamics that are worth highlighting in the context of phage therapy.
Bacterial killing by phage is dependent on phage particles adsorbing to
the target bacteria [9]. Phage-bacterium binding kinetics may be
modelled as a simple ﬁrst order process with respect to the con-
centrations of bacteria and phage populations respectively [8,63].
Payne and Jansen [63] developed a mathematical model focusing on
the dynamics of phage infection of bacteria during the bacterial ex-
ponential growth phase. Levin and Bull [8] extended the model to in-
clude the eﬀect of bacterial mutation leading to phage resistant popu-
lations and the eﬀect of the immune response in combating bacterial
infections. Cairns et al. [9] ﬁtted in vitro phage-bacteria population
dynamics (time series data for Campylobacter jejuni) to extract interac-
tion parameters; the model included the rate at which resistant cells
arise by mutation from a susceptible population. Their model and that
of Levin and Bull [8] helps explain the in vitro observations (see Tanji
et al. [64]) showing an increase in concentration of resistant bacteria in
the presence of high concentrations of phage. In in vitro studies, the
rate of growth of resistant bacteria tends to be similar to that of the
original susceptible population. The ﬁtted rate of mutation was found to
be of the order of 10−5 h−1 (which is relatively fast). An alternative
explanation may be the presence of a small number of resistant cells
present at the start of the culture [9]. Measures to suppress growth of
resistant bacteria would include use of multiple phage strains in-
corporating phage that bind to diﬀerent receptors. The purpose of the
modelling is to illustrate a number of important features that provide
insights that may help inform in vivo phage therapy. Modelling can be
used to determine the eﬀects of parameters such as the dose of phage
delivered, the rate at which it is delivered (e.g. controlled release) or
bacteria growth rate, on phage-bacteria population dynamics and on
phage therapy outcomes. It may be used to help interpret results of in
vivo studies and inform the design of future studies.
We have undertaken numerical simulations of phage-bacterium
population dynamics for an acute infection model to highlight key
features including the dynamics of phage interaction with bacteria
during the exponential growth phase (model equations and parameters
used for simulations are laid out in Appendix A). Our model is similar to
that of Levin and Bull [8] for phage-bacteria interactions incorporating
phage resistant bacteria arising from bacteria mutation (we have used
the mutation rate used by Cairns et al. [9]; we haven't included a model
of the immune response). Phage growth is determined by a number of
parameters, the phage-bacteria adsorption rate constant, burst size (the
number of phage released for each infected bacteria), latent period
(following infection how long it takes for the phage replication cycle to
be completed in a bacterial cell), the bacteria growth rate, phage and
bacteria elimination rates due to host response and the initial con-
centrations of bacteria and phage [65]. A unique feature of our model is
that we have also incorporated the eﬀect of controlled release of phage
which to our knowledge has not previously been done.
Our simulations demonstrate the conditions under which phage
therapy may be able to limit the proliferation of bacterial populations.
High phage densities are needed in order to arrest the growth of phage
susceptible bacteria (Fig. 1 a, b). We have indicated an arbitrary upper
bacterial concentration threshold of 109 CFU/ml as an aid to guide the
reader's eye. Adsorption of phage to bacteria results in an initial drop in
phage concentration (see experimental results by Cairns et al. [9] with
Campylobacter jejuni showing this). The timing of rapid in situ phage
ampliﬁcation is highly dependent on the concentration of the bacteria
[9]. Successful ampliﬁcation of phage is dependent on high bacterial
concentration hence eﬃcient killing is not achieved until both phage
and bacteria concentration increase signiﬁcantly (Fig. 1 b). See also
experimental results in support of this in the work by Tanji et al. [64].
Resistant bacteria quickly become the dominant population (Fig. 1 a, b)
unless a phage mixture (cocktail) is used containing high doses of the
diﬀerent phage strains capable of killing the resistant mutant popula-
tion (Fig. 1 c, d). It is known that phage clearance mechanisms rapidly
reduce the phage concentration in the absence of host bacteria [58].
Using high initial bacterial concentration, a high phage dose is
quickly able to arrest the rise of bacterial growth (Fig. 2 a). Tanji et al.
[64] show this for E. coli using an in vitro chemostat experimental
system. However, if low starting concentrations of bacteria are present,
phage concentrations decay signiﬁcantly and phage are unable to am-
plify and achieve a suﬃciently high concentration to eradicate the in-
fecting bacteria until the bacteria have had time to grow bacterial
numbers substantially (Fig. 2 b). In such circumstances it takes time for
the bacterial population to grow before phage are able to adequately
multiply in situ and then arrest bacterial growth (experimental results
by Cairns et al. [9] show this). During this delay phage concentrations
may decay signiﬁcantly thereby resulting in poor phage therapy out-
comes. If phage are administered prophylactically too early prior to
infection or at the early onset of infection (when the bacteria con-
centration is low), clearance of phage by the host immune system or by
other mechanisms (e.g. shortening of intestinal transit times during
diarrhoea) may result in lowering of the in situ phage concentration
resulting in poor phage therapy outcomes (Fig. 2 b). Under such con-
ditions encapsulation may be a good strategy (Fig. 2 c). Encapsulation
of phage and their slow controlled release may help in ensuring that the
in situ phage concentration remains at a therapeutically eﬀective level
(over a realistic time period) allowing phage to amplify once the bac-
teria concentration increases to levels suﬃcient for in situ phage am-
pliﬁcation (Fig. 2 c).
Our simulations show that the in vivo phage concentration at the
site of infection is an important parameter governing the eﬃcacy of
phage therapy. Loss of phage activity during formulation and storage,
or phage inactivation due to the in vivo environment (e.g. acidic pH of
the stomach or enzymatic activity) may result in poor phage therapy
outcomes. These issues have received little attention in phage therapy
literature. Research is therefore needed in the area of phage formula-
tion to ensure phage titre remains stable during storage (e.g. over a
24 month period). Phage cocktails necessitate careful consideration of
formulation conditions as each type of phage making-up the cocktail
may require individually tailored formulations to ensure phage viability
and stability during storage.
3.5. Phage therapy animal studies – acute infections
3.5.1. Key points arising from reviewing phage therapy literature focusing
on acute infections in animals
Most in vivo phage therapy studies (in animals) have delivered the
phage and bacteria dosed simultaneously together (Table 1). Typically,
a high ratio of phage to bacteria has been used (phage concentrations
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10–1000 times higher than the infective dose of bacteria). Phage
treatment of acute infections caused by both Gram positive and Gram
negative bacteria have been studied (Table 1).
Phage have been administered using diﬀerent delivery routes in-
cluding intramuscular [34,66–69], subcutaneous [29,31–34,42], in-
traperitoneal [31,34,67,70–72], intravenous [29,68], intranasal
[26–28,42], orogastrically [57,58,64,70,73–81], intracranial [69] or
added to animal feed [75,82] or water [83]. The route of phage admin-
istration has been shown to aﬀect eﬃcacy outcomes [34,42,66]. In a
number of studies intraperitoneal delivery was shown to result in higher
concentrations of systemic phage, delivered earlier, remaining in circu-
lation for longer and allowing phage access to numerous host organs in-
cluding lungs, spleen and kidneys [34,32]. Better therapy outcomes were
seen for lung infections when phage were dosed using the intraperitoneal
or systemic route instead of using pulmonary delivery [31].
A number of in vivo animal studies have shown dose dependent
recoveries with high doses of phage resulting in better clinical outcomes
[33,66–68]. Delaying the start of phage treatment post-infection typi-
cally resulted in poor outcomes [33,67,68]. This was attributed to high
growth rates resulting in high concentrations of replicating bacteria
overwhelming the immune system with bacterial toxins [68].
Inoculation of control animals (not infected with bacteria) with high
phage doses was shown not to result in adverse health symptoms in
animals [67]. A number of in vivo studies reported rapid drop in phage
titre in the absence of host bacteria suggesting clearance by the host
immune response or other removal mechanisms [32,58]. Encapsulation
of phage in liposomes (for treating gastrointestinal infections) was
shown to increase the retention time of phage in the host with better
therapeutic eﬃcacy [31].
In situ ampliﬁcation of phage (at high phage doses) has been ob-
served in some instances [71]. Frequent administration of high phage
doses was found to result in better outcomes [64,76,78,80]. This is an
important point considering in vivo phage-bacteria dynamics. Better
phage therapy outcomes were noted when both phage and bacteria
concentrations tend to be high. Phage titre reduction in vivo may result
in poor phage therapy results when bacterial concentrations may be too
low for rapid phage ampliﬁcation. Reduction in phage titre may also
explain results of a number of studies that evaluated prophylactic phage
therapy with mixed results [70,73,75,79,80,83]. Use of phage cocktails
rather than single phage was found to yield better results [58,64] and in
some instances reduced the chances of ﬁnding phage resistant mutants.
A number of studies did ﬁnd phage resistant mutants [66,69]. The
complex architecture of the intestinal tract was found to present a
challenge for phage therapy. Temporary reduction in bacterial faecal
shedding attributed to phage treatment was typically followed by an
increase in faecal bacterial concentration without clearance of gastro-
intestinal infections [57,58,75,77,83].
Results of a number of animal studies suggest that stopping rapid
ampliﬁcation in bacterial numbers is an important factor in therapy
outcomes [26–28]. Arresting infection by early administration of high
phage dose when the bacteria are also highly susceptible to phage in-
fection was found to correlate with better phage therapy outcomes.
Administration of high concentrations of phage may result in multiple
phage particles adsorbing per bacterial cell which may lead to bacterial
cell lysis due to phage binding without phage virion production. Del-
bruck [84] coined the term "lysis from without". Large numbers of
phage adsorbing to the bacterial cell wall may lead to cell wall damage
due to the enzymatic action of tailed phage enzymes acting on the cell
envelope/wall [85].
Infection is generally induced in animal models with a single bac-
terial species, however, even single bacterial triggered infections
necessitate the use of phage cocktails rather than single phage treat-
ments. This is because phage mixtures targeting diﬀerent receptors
reduce the probability of encountering phage resistant bacterial mu-
tants (see modelling section above). Denou et al. [86] suggest that
cocktails containing between 10 and 16 phage may be needed to cover
between half and two thirds of E. coli strains (representing the ﬁve main
pathogenic types isolated from patients suﬀering from diarrhoea) in
order to cure E. coli related diarrhoea. Cocktails of phage may also
provide synergistic eﬀects such as access to bacteria in mucus and
bioﬁlms with a phage possessing bioﬁlm/mucus degrading enzymes
enhancing access within mucus/bioﬁlms for other phage better suited
to killing the bacteria [87]. This point has signiﬁcant implications for
phage formulation since diﬀerent phage within a cocktail may need
diﬀerent formulation ingredients to aid shelf life during storage in order
to retain infectivity. A number of animal studies (discussed below) have
shown that regular repeated doses of high phage titres resulted in better
outcomes rather than a single dose. Encapsulation of phage in con-
trolled release systems may allow constant release (zero order release)
of phage e.g. using readily available technologies such as osmotic
pumps or constant reservoir systems used in the pharmaceutical in-
dustry. Vandenheuvel et al. [88] discuss the importance of phage sta-
bility and the unacceptability of phage titre drop in view of pharma-
ceutical regulations. The results of animal studies (above) provide
strong evidence of the need to deliver high titres of phage at the site of
infection. Phage dose-response studies in animals suggest that a drop in
titre of 1-log during storage could result in phage therapy failure. Re-
duction in phage titres due to phage inactivation attributed to stomach
acidity was partly blamed for failure of a recent clinical trial aiming to
show reduction in acute bacterial diarrhoea symptoms in children using
phage therapy [35].
The pharmacokinetics of phage delivery to various animal organs
depended on the route of administration. In a number of studies, in-
traperitoneal delivery of phage resulted in higher concentrations of
phage in systemic circulation and those found in diﬀerent organs in-
cluding lungs. Encapsulation of phage in liposomes was found to in-
crease the length of systemic circulation of phage. There is some evi-
dence in literature that phage encapsulated in liposomes may enhance
delivery to intracellular infections (discussed later).
Bacteriophages have a narrow host range. They are speciﬁc not only
in terms of killing a particular species, but often they only target a sub
set of strains within the species. In an outbreak situation where the
causative agent and strain information is available, selection of a re-
levant phage for therapy may not be a problem [26]. However, as phage
host range is narrow, rapid diagnosis of the causative agent and the
strain would beneﬁt accurate phage selection. Most phage therapy
studies in model animal systems (discussed above) have used simple
phage solutions prepared immediately prior to use. Phage banks may
need to regularly screen phage against common infection causing
strains and manufacture these in batches to make them readily avail-
able. The phage would need to be processed in such a manner so as to
ensure long shelf life (typically 12 months) e.g. formulated in excipients
and spray dried or freeze dried to ensure accurate dosage at the time of
therapy.
Characterisation of the kinetics of phage binding to target bacterium
and in vitro evaluation of phage-bacterium population dynamics as part
of the selection tests (e.g. host range, presence of integrase genes) as-
certaining the suitability of phage for therapeutic use is often over-
looked and needs greater attention.
A detailed list of literature studies covering phage therapy in various
animal models is provided in Table 1 and more detailed commentaries
on some selected papers are now given as follows.
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3.5.2. Parenteral phage delivery (animal studies)
A number of animal studies have looked at parenteral delivery of
lytic bacteriophage following delivery of an infectious dose of bacteria
(Table 1). Early work by Smith et al. [66] demonstrated the potential of
intramuscular and intravenous administration of phage (108 PFU/
mouse) against E. coli infection (intramuscular injection of LD50 dose of
107 CFU/mouse) in a mouse model. The eﬀect of delaying treatment
(8 h delay in treatment) showed favourable results. Prophylactic
treatment up to 2 days before induced infection resulted in signiﬁcant
protection in animals. Intramuscular injection of bacteria resulted in
high concentration of bacteria at the site of infection and in the blood,
spleen and liver ~24 h post-inoculation. Within 5 min of phage ad-
ministration, high phage numbers were found in the muscle, blood,
spleen and liver. They persisted for shorter durations in the blood and
liver compared with the inoculated muscle and spleen. Phage resistant
mutants were found at the site of infection but were considered much
less virulent.
Barrow et al. [69] inoculated (intramuscularly (septicemia model)
and intracranially (meningitis model)) newly hatched and 3 week old
chickens with E. coli and phage and showed dose dependent recovery.
Administration of higher concentration of phage resulted in sig-
niﬁcantly better outcomes. The same study also evaluated oral E. coli
administration to Aberdeen Angus Calves with concomitant in-
tramuscular phage delivery. The phage were unable to arrest the in-
testinal growth of E. coli and the presence of phage resistant mutant
strains were found in the gut one day following E. coli inoculation and
two days later in the blood (indicating translocation of phage from the
gut into blood e.g. through intra-abdominal abscesses) of the infected
calves. This study showed the importance of phage dose and route of
delivery on therapy outcomes (mortality).
Table 1
Summary of phage therapy animal studies to treat acute local, systemic, gastrointestinal and pulmonary bacterial infections.
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7 2-8 *
[69] Ec Se bp 6 2-6
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[71] Sa Sy bp 9 9-11 *
[33] Sa W bp 8 6-9 *
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b
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[29] Sa Sy L bp bp 8 7-9(R) *
[31] Kp Sy pΦ b 4 9, 7(E) *
[69] Ec G p b 10 10 *
[83] Ec G b p 4-8 5-6
[64] Ec G bp* 9 8-10(R)
[73] Cj G bp 5 9-10 */
[70] Pa G bp bp 6-10 10 *
[74] Se G bp 4 8
[75] Ec G bΦ 11 10-11
[57] Ec G bΦ* 5 ~5(R)
[76] Cd G bp* 3 ~8(R) */
[78] Se G bΦ 7 10(R)
[77] Se G bΦ 7 10(R)
[58] Vc G bp* 5, 8 5-7, 8 */
[58] Vc G bp* 8 9 */
[59] Se G bΦ 9 ~10(R)
[80] Se G bp 6 ~10(R)
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[92] Ec P p p p 6-8
[90] Ec P p b 4 7-9
[42] Bc P p p b b 7-9 7-9 *
[26] Pa P bp 7 7-9 *
[27] Pa P bp 7 8
[28] Pa P bp 6 6-8 *
[31] Kp P pΦ b 4 2-4 *
[32] Kp P p b 7-8 9-11 *
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Using a Enterococcus faecium bacteremia mouse model Biswas et al.
[67] investigated the eﬀect of phage dose in E. faecium infected mice
(concomitant delivery of phage and bacteria delivered via in-
traperitoneal injection) as well as the eﬀect of delaying the start of
phage treatment (5 h, 8 h, 12 h, 16 h and 24 h after inoculation with
bacteria). The severity of illness symptoms exhibited by mice was
correlated with the bacterial concentration in the blood and this was
shown to be dependent on the concentration of phage used for treat-
ment. Mice inoculated with high titres of phage suspension (without
infection with bacteria) showed no adverse symptoms. 24 h delay in
phage treatment resulted in 60% (3 out of 5) of the mice dying after
96 h. The dosage and the timing of the delivery of phage were found to
be important in arresting bacterial growth and in mice recovery.
Cerveney et al. [68] evaluated the eﬃcacy of phage (used locally
and systemically) against the Gram negative bacterium Vibrio vulniﬁcus
(causes septicemia after ingestion of contaminated oysters and necro-
tising fasciitis in contaminated wounds) in an iron-dextran-treated
mouse model. Bacteria were injected subcutaneously whereas phages
were injected intravenously. A high phage dose (108 PFU) was given
(the animal was subcutaneously given a dose of 106 CFU of a highly
virulent clinical isolate of the bacterium to create a skin lesion) and
shown to reduce the bacterial burden of the lesion and in the bacterial
CFU in the liver (14 h post-infection). Experiments with delayed
treatment (≥6 h) post-infection showed lack of eﬃcacy and resulted in
treatment failure. Dose response studies with animals infected with
103 CFU of bacteria and immediately given either 104, 106 or 108 PFU
of phage showed only the higher concentration of phage dose at
108 PFU aﬀorded signiﬁcant protection to the treated mice. The need
for high phage dosages was attributed to the short doubling time of the
bacterium (45 min) which resulted in a high growth rate of bacteria
post-infection. The study also evaluated the half-life of phage (2.2 h at
108 PFU) injected intravenously and found that phage concentrations in
blood rapidly decreased due to clearance by the reticuloendothelial
system. Phages are known to induce antibodies aiding their removal
from circulation as well as neutralising their interaction with bacteria
[30,42,89].
Matsuzaki et al. [71] showed dose dependent pharmacodynamics
using concomitant intraperitoneal injection of S. aureus followed by
phage (delivered within 60 min of bacterial inoculation) with high
concentrations of phage observed in blood (at high phage doses
1011 PFU to treat 109 CFU of S. aureus) indicating in situ ampliﬁcation
of phage. In a rabbit model of wound infection induced by S. aureus,
Wills et al. [33] used a high dose of phage (109 PFU, delivered sub-
cutaneously) whilst simultaneously infecting with S. aureus (~108 CFU)
to show protection against abscess formation. The study also carried out
a dose response study and showed that only at the highest phage dose
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Fig. 2. Population dynamics of bacteria and phage.
Blue lines – phage concentration; red lines – bacteria concentration.
(a), (b) – eﬀect of phage dose (104–108 PFU/ml) and initial bacteria concentration (104, 107 CFU/ml);
(c) - eﬀect of continuous sustained delivery of phage for 1 h, 4 h and 10 h (solid, broken and dashed lines accordingly). (For interpretation of the references to colour in this ﬁgure legend,
the reader is referred to the web version of this article.)
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Fig. 1. Population dynamics of bacteria and phage.
Blue lines – phage P1 (solid line) and P2 (dashed line). Red lines – bacteria B1 (solid line) and B2 (dashed line); B2 is resistant to P1.
(a) – low dose of single phage (P10≈ 103 PFU/ml) is insuﬃcient to prevent bacteria concentration exceeding upper threshold;
(b) - high dose of phage (P10≈ 106 PFU/ml) arrests B1 growth, but phage resistant mutant bacteria B2 grows unchecked;
(c) and (d) - mixture of two diﬀerent phage; (c) - low dose of P2 is insuﬃcient to prevent resistant bacteria B2 concentration exceeding upper threshold; (d) - high dose of both phage
prevents both bacteria concentrations from reaching upper threshold. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this
article.)
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was there an absence of abscess formation. The median area of abscess
formation and the concentration of bacteria found in the abscess (CFU/
ml) showed an inverse correlation with the dose of phage given. The
eﬀect of delaying treatment (by giving a high phage dose (109 PFU) 6 h,
12 h and 24 h after bacterial infection) resulted in abscess formation in
all animals.
McVay et al. [34] in a mouse burn wound model compared in-
tramuscular, subcutaneous and intraperitoneal routes of phage delivery
using a cocktail of Pseudomonas aeruginosa phage. Phage administered
by the intraperitoneal route (~108 PFU) aﬀorded better protection
against P. aeruginosa infection (~102 CFU injected subcutaneously at
the burn site) with higher concentrations of phage found in the blood,
spleen and liver of animals. Phage resistant mutants were not found
even in animals that had died. Intraperitoneal delivery of phage was
found to result in delivery of higher phage dose, delivered earlier into
the blood and other tissues, and delivered for a more sustained period
of time.
Capparelli et al. [29] intravenously infected mice with S. aureus
(dose, 108 CFU/mouse) followed by immediate intravenous injection of
phage (107, 108 or 109 PFU/mouse). All the mice in the control group
(infected but not treated with phage) and those treated with the lowest
phage dose (107 PFU/mouse) died within 4 days (10/10 mice). The
mice treated with the intermediate dose (108 PFU/mouse) were only
partially protected (2/5 mice survived) whilst mice treated with the
highest dose (109 PFU/mouse) all survived (5/5 survived). 4 days after
phage injection, high concentrations of bacteria (in kidney, heart,
spleen and lung) were recorded for the untreated controls whereas no
bacteria were found in the same organs for mice treated with 109 PFU/
mouse. Lack of phage ampliﬁcation in blood (attributed to a replication
threshold) was in all likelihood down to the low concentrations of
bacteria in blood making it diﬃcult to accurately monitor phage am-
pliﬁcation under such conditions. At low levels of systemic infection (S.
aureus dose 106 CFU/mouse) a 10 day delay in phage therapy
(109 PFU/mouse) cleared S. aureus infection in the animals. Capparelli
et al. [29] also evaluated the eﬃcacy of phage therapy for local S.
aureus infections (subcutaneous injection of bacteria and phage). Con-
comitant injection of phage prevented formation of abscess in the mice.
Delayed phage treatment (phage administration 4 days after onset of
infection) did not prevent abscess formation. There was a reduction in
the bacterial load in the abscess and the weight of the abscess when
multiple injections (4 injections/day) were used. Repeated doses were
found to be more eﬀective than a single dose in reducing the bacterial
load in the abscess and the weight of the abscess. S. aureus can adopt an
intracellular lifestyle. Capparelli et al. [29] also evaluated the eﬃcacy
of phage activity in a S. aureus intracellular infection mouse peritoneal
macrophage cell line model. Phages were not able to penetrate the
macrophages and kill the intracellular S. aureus. Using a Trojan horse
approach, S. aureus infected with phage were able to access the in-
tracellular compartment of the macrophages and kill S. aureus cells
residing within. This study suggests the possibility of encapsulating
phage in systems that may facilitate access to intracellular compart-
ments where infecting bacteria may be targeted (more on this later in
the section on encapsulation of phage in liposomes to target in-
tracellular pathogenic bacteria).
3.5.3. Oral phage delivery (animal studies)
Animal studies using oral delivery of bacteriophage have focused on
acute gastrointestinal infections (Table 1). The main concern here is
phage inactivation due to the acidic and proteolytic environment of the
stomach. The use of antacids e.g. calcium carbonate or bicarbonate
prior to infection challenge or with phage delivery in order to neutralise
the stomach acidity has been common practice in a number of studies
[23,58,64,76,78]. A few studies have employed encapsulation of phage
in polymer or liposome encapsulation systems [57,75,77,78]. Colom
et al. [77] showed that encapsulation of phage in liposomes resulted in
signiﬁcantly longer periods of phage retention (several days longer) in
the caecum of chickens and lower number of bacteria colonizing the
gut.
Chibani-Chennouﬁ et al. [83] showed survival of T4-like E. coli
phage through the gastrointestinal tract of mice when added to
drinking water. The minimal oral dose for consistent faecal recovery
was 104 PFU/ml of drinking water. E. coli infected mice showed 105
fold ampliﬁcation of phage with concomitant drop in faecal E. coli
counts from 108 to 104 CFU/ml. However, phage sensitive E. coli con-
centration recovered post-treatment even when residual high faecal
phage titres were present, suggesting phage sensitive E. coli were able to
replicate in the gut and that the concentration of phage present in the
gut was not high enough to eliminate the E. coli. The authors suggested
sites in the gut where E. coli may be protected from the phage (cells
growing as microcolonies in the mucin layer). Other studies have also
reported an initial reduction in faecal shedding followed by recovery of
bacterial numbers [64,73,74].
Tanji et al. [64] used a chemostat (in vitro studies) to investigate the
dose and frequency of phage administration on phage-E. coli population
dynamics. The chemostat experiments suggested repeated high doses of
phage were needed to keep the E. coli concentration in check. The re-
sults informed phage therapy in mice where E. coli was orally ad-
ministered (dose 109 CFU/mouse) using a plastic sonde directly into the
stomach followed 2 days later with phage cocktail delivery to the sto-
mach in a similar manner (single dose of 108 PFU/mouse or 1010 PFU/
mouse or repeated daily doses of 1010 PFU/mouse). Daily administra-
tion of phage resulted in a stable concentration of phage in the faeces
and signiﬁcant reduction in the E. coli concentration in the faeces. A
cocktail containing three phage was employed however, the con-
centration of phage in the faeces suggested one phage dominated and
was present at a signiﬁcantly higher concentration in comparison with
the other two (indicating diﬀerences in the pharmacodynamics of the
three phage). Nine days after the start of phage therapy with daily
administration of phage, no E. coli were detected in the lower small
intestine and the colon of treated mice. A number of studies have used
repeated dosing of phage and shown reduction in intestinal coloniza-
tion with bacteria [57,76–80]. This study stands out as one of very few
where elimination of E. coli was observed for treatment of gastro-
intestinal infections.
Wagenaar et al. [73] evaluated the prophylactic or therapeutic ef-
ﬁcacy of phage treatment for control of Campylobacter jejuni (C. jejuni,
which colonizes young broiler chickens, is an important human pa-
thogen and is the most common cause of bacterial gastroenteritis
worldwide). A modest 1-log reduction in bacterial CFU counts
(~109 CFU/g faeces) was observed in both the prevention and the
therapeutic groups compared with the control group (not given phage).
Phage selection was on the basis of activity across a wide range of C.
jejuni strains.
Watanabe et al. [70] investigated the eﬃcacy of phage therapy
using a murine model of gut-derived sepsis caused by P. aeruginosa
(resembling the clinical pathophysiology of septicemia in humans).
Administration of cyclophosphamide (to suppress the immune system)
and ampicillin (to disrupt the gut microﬂora) was used before oral in-
oculation with P. aeruginosa to achieve gut-derived sepsis. Intestinal
overgrowth in the gut resulted in P. aeruginosa crossing the gastro-
intestinal mucosal barrier by bacterial translocation and spreading
systemically in the mice. Timing of phage treatment was found to in-
ﬂuence the eﬃcacy of phage therapy. Mice treated with a high dose of
phage 1 day post-infection with P. aeruginosa showed improved survival
rates over controls (mice not treated with phage). Average numbers of
viable bacteria in blood, liver, spleen and mesenteric lymph nodes were
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signiﬁcantly lower in phage treated mice compared with controls.
Faecal counts were also lower in phage treated mice as were cytokine
levels in serum and liver. Compared to oral administration, intravenous
and intraperitoneal administrations of phage were found to result in
better outcomes. The infectious dose was 106 CFU/mouse with phage
dose of 1010 PFU/mouse. Only simultaneous intraperitoneal adminis-
tration of phage and bacteria resulted in improved mice survival.
Andreatti Filho et al. [74] showed short term (24 h after infection)
reduction in Salmonella enterica detection (dose ~ 104 CFU/chick) from
caecal tonsils following phage administration (phage cocktail con-
taining 45 diﬀerent phage administered using oral gavage, 108 PFU/
chick). However, no signiﬁcant diﬀerences were observed between the
phage treated and the control groups after 48 h. The cocktail used
wasn't suﬃciently well characterised in terms of individual phage
concentrations and the kinetics of individual phage binding and their
lytic activity; a recurring theme in the reading of literature in this area.
Stanford et al. [75] encapsulated E. coli phage in a commercial pH
responsive methacrylate polymer using a spray drying process (a 1 log
reduction in activity due to spray drying was noted). Oral inoculation of
1011 CFU/steer of a ﬁve strain mixture of E. coli O157:H7 was followed
either by encapsulated phage given as a single oral bolus (1010 PFU/
steer) or mixed-in with feed (1011 PFU/steer). Higher concentration of
faecal shedding of phage (2-log higher) was noted for encapsulated
phage given as part of the feed rather than bolus suggesting diﬀerences
in in situ phage concentrations. Phage were shown to replicate in situ
over a period in excess of ten days following treatment and continued to
be shed 42 days post-treatment (albeit at lower concentrations in com-
parison with the ﬁrst ten days) however, no signiﬁcant diﬀerences in
reduction in E. coli shedding was observed between the phage treated
steer and the controls. Insuﬃcient understanding of the in vivo phar-
macodynamics of the phage against the E. coli strains may have resulted
in poor outcomes of phage therapy.
To address the issue of human gastroenteritis caused by E. coli
transmitted through farm animals, meat and poultry Abdulamir et al.
[57] studied the eﬀect of a cocktail of 140 lytic E. coli speciﬁc phage
encapsulated using a hydroxypropyl methylcellulose (HPMC) based
enteric coating. The capsules (ZeinPharma Germany, GmbH, Germany)
encapsulating the 140 E. coli speciﬁc phage were administered orally in
rats. A concentration of 107 PFU/ml phage suspended in an aqueous
solution of sodium bicarbonate and an injectable master mix in lambda
buﬀer were compared with HPMC capsules carrying the phage cocktail
in lambda buﬀer. HPMC encapsulated phage were found to give better
results with a reduction in E. coli shedding of up to 4-log.
Nale et al. [76] used a hamster model for the oral delivery of either
single or a mixture of phage against Clostridium diﬃcile. A hamster
model of acute C. diﬃcile infection (CDI) was used. The model reﬂected
some of the clinical features of CDI including toxin-mediated diarrhoea
and tissue pathology. Animals were given sodium bicarbonate orogas-
trically to reduce stomach acidity. Animals were infected with
~103 CFU/hamster of spores and subsequently treated with
~108 PFU/hamster of either a single phage or a cocktail of phage. The
ﬁrst dose was given at the time of infection with further doses every 8 h
until the scheduled end-point of 36 h (toxin production in untreated
animals is limited up to this time point in the cecum and colon thereby
allowing assessment of the eﬀect of phage treatment on colonization in
the absence of toxin related symptoms). At this time point, animals
were culled and enumeration of total bacterial load (spores and vege-
tative cells) in the cecum and colon was undertaken. Phage treatment
with certain combination of phage mixtures was shown to reduce
bacterial load in the cecum and colon however, results were variable.
This variability was attributed to the ratio of phage to bacteria present
at various locations in the cecum and colon during the initial phase of
bacterial outgrowth. In a separate experiment using the earlier protocol
but continuing regular 8 h phage treatments delayed onset of symptoms
by 33 h (due to toxin production) in phage treated animals compared to
untreated animals was observed. Complete protection was not
achieved. The amount of phage delivered to the cecum or colon was not
quantiﬁed however, high titres of phage 107 PFU/ml were recovered
from the cecum and colon.
Recently Colom et al. [77] used a cocktail of three Salmonella phage
individually encapsulated in cationic liposomes to treat Salmonella in-
fection in commercial broilers under farm-like conditions. Bacter-
iophage retention in the chicken caecum was investigated by giving an
oral dose of phage (1010 PFU/chicken) of either free phage (1:1:1
mixture of the three phages ϕ20, ϕ78 and ϕ87) or liposome en-
capsulated phage cocktail to 63 1-day old chickens. Caecum samples
collected from euthanized animals showed signiﬁcantly higher numbers
of chickens treated with encapsulated phage had phage in their caecum
48 h and 72 h later. Bacteriophage therapy against Salmonella was
evaluated over 17 days in chickens orally administered either the free
phage cocktail or encapsulated phage cocktail (bacterial dose at day 0:
107 CFU/chicken, phage dose 1010 PFU/chicken). Oral doses of phage
were administered daily for 9 days (from day −1 to day 7 after Sal-
monella infection). Over the course of daily phage therapy (days 1, 3, 6)
both groups receiving phage treatment showed lower (~3 log reduc-
tion) Salmonella concentration in the cecum compared with the control
group. Once daily phage treatment had stopped (day 8 onwards), Sal-
monella concentration in the free phage treated group returned to levels
similar to the control group. However, the liposome encapsulated
phage treated group continued to show lower Salmonella concentration
in the cecum compared with the control group up to day 15. Salmonella
infection was not eradicated by either treatment which was attributed
to high initial Salmonella concentration in the cecum (106 CFU/g of
cecum), which was considered higher than naturally occurring levels.
In a separate study, Colom et al. [78] used a cocktail of three Sal-
monella phage individually encapsulated in alginate microparticles
containing CaCO3 to treat Salmonella infection in commercial broilers
under farm-like conditions. Bacteriophage retention in the chicken
caecum was investigated by giving an oral dose of phage (1010 PFU/
chicken) of either free phage (1:1:1 mixture of the three phages ϕ20,
ϕ78 and ϕ87) or alginate/CaCO3 encapsulated phage cocktail to 63 1-
day old chickens. Caecum samples collected from euthanized animals
showed signiﬁcantly higher numbers of chickens treated with en-
capsulated phage had phage in their caecum 48 h and 72 h later. Bac-
teriophage therapy against Salmonella was evaluated over 17 days in
chickens orally administered either the free phage cocktail or en-
capsulated phage cocktail (bacterial dose of day 0: 107 CFU/chicken,
phage dose 1010 PFU/chicken). Oral doses of phage were administered
daily for 9 days (from day−1 to day 7 after Salmonella infection). Over
the 15 days, a signiﬁcant reduction (between 2 log and 3 log) in Sal-
monella concentration was noted for the group treated with en-
capsulated phage. At days 8, 10 and 15 the encapsulated phage treated
group had lower Salmonella concentration compared with the free
phage treated group showing better therapy outcomes using the en-
capsulated phage. The mucoadhesiveness of the microparticles and the
slow sustained release kinetics were thought to be important factors in
explaining these results. Similar concentration levels of phage were
noted in the caecum for both encapsulated and free phage
(~103–104 PFU/g). Phage persisted in the caecum even after phage
treatment was stopped with higher phage concentrations noted for the
free phage treated animals. Salmonella infection was not eradicated by
either treatment. The authors reported that they did not ﬁnd any phage
resistant bacteria in the phage treated groups. Hence the persistence of
Salmonella infection was not attributed to phage resistant mutants.
A diﬀerent study using alginate microencapsulated Salmonella
phage to treat pigs [59] showed that co-administration of Salmonella
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with a phage cocktail resulted in reduction in pig intestinal Salmonella
concentration (~2 log reduction). Yen et al. [58] recently reported
studies with mice and rabbits on the prophylactic eﬀect of phage
therapy to treat cholera. Oral administration of a cocktail of three Vibrio
cholera lytic phage up to 24 h prior to infection with V. cholera reduced
colonization and cholera-like diarrhoea. Complete elimination of bac-
teria was observed at short prophylaxis times (3 h), high phage dose
(106–107 PFU/mouse) and low bacterial infection dose (105 CFU/
mouse). Phage administration in negative controls (i.e. not inoculated
with bacteria) showed a signiﬁcant drop in phage titre (3 log reduction
in mice) 12 h following phage treatment, indicating phage elimination
by the host.
3.5.4. Pulmonary phage delivery (animal studies)
Pulmonary delivery of phage has been achieved using a variety of
methods including nasal instillation [26–28,42], aerosolization of li-
quids using a nebulizer [90,91] and intraperitoneal injection [31,32].
Carmody et al. [42] found intraperitoneal delivery of phage resulted in
reduction in an acute lung Burkholderia cenocepacia infection in mice
compared with nasal instillation whereas Oliveira et al. [92] found
intramuscular injection better than oral administration or using a spray.
The dose of phage, concentration of bacteria and the timing of
phage therapy were found to have a signiﬁcant impact on phage
therapy outcomes. In most cases delivering high doses of phage im-
mediately or soon after inoculation of lungs with bacteria resulted in
better outcomes [26,28,32]. Singla et al. [39] compared treatment of
induced acute K. pneumonia infection in mice with free phage versus
liposome encapsulated phage and showed that high dose of en-
capsulated phage gave better outcomes given up to 48 h prior to K.
pneumonia infection. A number of studies reported in situ ampliﬁcation
of P. aeruginosa and K. pneumonia phage [26,28,39]. Phages were ra-
pidly cleared from the lungs of mice [28] hence high phage dose was
needed for prophylactic treatment 24 h prior to bacteria inoculation
[26]. Eﬀective phage therapy reduced the host inﬂammatory response
[26,28,39].
Phages for treating respiratory infections caused by P. aeruginosa, B.
cenocepacia, E. coli and K. pneumonia are available. Eﬃcacy of phage
activity against clinical strains obtained from CF sputum and in rela-
tively early stage bioﬁlms has been shown [27,39]. Phages with lytic
activity have been shown to possess hydrolases that degrade bacterial
exopolysaccharides. Animal studies have shown that a number of phage
delivery routes are eﬀective for phage delivery to treat acute lung in-
fections. However, further work needs to be done to show the eﬃcacy
of phage therapy in chronic infections against more mature bioﬁlms
containing well established polymicrobial communities in both in vitro
and in vivo systems.
Oliveira et al. [92] evaluated the eﬀect of the route of administra-
tion (oral, direct spray on beaks and intramuscular injection) and the
concentration of phage in the dose (106, 107 and 108 PFU/chicken) in
the dissemination of 3 lytic E. coli phage in the organs of chickens
(lungs, liver, duodenum and spleen). The focus of the study was on
controlling avian respiratory infections. Administration of phage using
intramuscular injection was found to be the best means of ensuring
phage dissemination in all tissues (including lungs). In the work by
Oliveira et al. [92], aerosol spray administration (details regarding the
spray generation were not given) allowed phage to be directly delivered
to the lungs. Suﬃcient details regarding the formulation of phage for
spray dose were not given, e.g. whether the spray droplet size dis-
tribution was suitable to aid droplet distribution in the lower re-
spiratory tract. The phage type, administration route and dose delivered
were all found to aﬀect the distribution of phage in the animal tissues.
Phages were rapidly cleared from the organs 10 h after administration.
Huﬀ et al. [90] determined the eﬃcacy of aerosol administration
(using an atomising nozzle and exposing the birds to the aerosol in a
closed chamber resulting in uptake by inhalation) of a cocktail con-
taining two bacteriophage (isolated against avian pathogenic E. coli) to
prevent an E. coli respiratory tract infection in broiler chickens. A severe
dose of 104 CFU/chicken (age 1 week) followed by a cocktail of phage
(a mixture of two phage at 107:108 PFU/chicken) resulted in reduction
in observed mortality (at age 3 weeks) compared with untreated con-
trols. The dose of phage was found to be important with lower con-
centrations of aerosolized phage aﬀording worse protection. The timing
of phage administration was also evaluated with phage treatment im-
mediately following E. coli infection showing positive eﬃcacy results.
However, results were mixed when phage were administered prior to or
3 days following E. coli challenge. Bacteria were cultured from swabs of
liver and air sacs but data on phage titres from the tissue samples were
not given.
Carmody et al. [42] investigated the therapeutic potential of bac-
teriophage in an in vivo mouse model of acute B. cenocepacia pul-
monary infection. Carmody et al. [42] compared intranasal inhalation
of bacteriophage with intraperitoneal injection of phage. 9 to 12 week
old mice were infected with 107 or 108 CFU B. cenocepacia (via tra-
cheotomy). 24 h after infection, mice were treated with either in-
tranasal inhalation (spray details not given) or intraperitoneal injection
of phage suspended in buﬀer (100 times higher dose of phage with
respect to the bacterial dose was given). 48 h after phage treatment,
mice were euthanized and lung tissue samples were analysed for B.
cenocepacia and phage. Mice treated with phage delivered via in-
traperitoneal injection had signiﬁcantly lower lung bacterial counts
compared with untreated control mice 48 h after treatment. The phage
concentration in the lungs of mice was not statistically signiﬁcant from
mock infected mice with similar dose of intraperitoneal treated phage.
The intranasal phage treatment did not result in a statistically sig-
niﬁcant reduction in lung bacterial counts, however, phage had am-
pliﬁed in the lungs and were present at concentrations above those in
mock infected mice with similar dose of inhaled phage. 24 h after in-
fection (but before phage treatment), bacteria were primarily found in
lung parenchyma in peribronchiolar and perivascular areas, occasion-
ally co-localised with alveolar macrophages. Relatively few bacteria
were found in the airway lumen. Bacteria were found in microcolonies
in lung parenchyma 72 h after infection (without phage treatment). The
concentration of phage in lungs of mice treated intranasally was 2 log
higher in comparison with intraperitoneal treated mice. Intranasally
administered phages were found co-localised with alveolar macro-
phages 48 h after treatment. This suggested that phage delivered in-
tranasally were sequestered by lung macrophages and therefore may be
unavailable to kill bacteria found in the lung parenchyma. Inhaled
phage did replicate in bacteria as the titres were found to be higher
compared with the control group. Phage may have been able to re-
plicate in bacteria taken-up by the macrophages. The phage in the
macrophages remained viable as determined by the high phage titres.
In intraperitoneally treated mice, phages were found in vascular and
perivascular areas and alveolar septa where phages were found co-lo-
calised with degraded bacteria. Results from the study indicated better
access of phage delivered intraperitoneally via systemic circulation to
bacteria than those delivered via pulmonary delivery. The site of
greatest bacterial killing may have been within the lung parenchyma
rather than the airway lumen. Phage delivered via the airway may not
have been able to eﬀectively penetrate the respiratory epithelium
where bacteria may have translocated from the lumen to the lung in-
terstitium. The lower concentration of phage in the lung following in-
traperitoneal delivery was attributed to a rapid decrease in bacterial
density and subsequent clearance of phage thereafter in the absence of
suﬃcient bacterial hosts.
Semler et al. [91] found aerosol delivery of B. cenocepacia phage in a
D.J. Malik et al. Advances in Colloid and Interface Science 249 (2017) 100–133
109
mouse lung infection model to be an eﬀective means of phage delivery
resulting in reduction in B. cenocepacia concentration over a three day
period post-infection. They also evaluated intraperitoneal delivery of B.
cenocepacia phage which resulted in higher concentrations of phage
delivered to the lung supporting the ﬁndings of Carmody et al. [42] that
intraperitoneal delivery of phage allows phage to access the lung. There
was however a discrepancy between the results of Semler et al. [91] and
Carmody et al. [42] with regard reduction in mouse lung bacteria
concentrations for phage delivered using the intraperitoneal route. This
may be explained by low concentrations of bacteria present in the lung
for experiments carried out by Semler et al. [91] which may have re-
sulted in poor in situ phage ampliﬁcation.
Debarbieux et al. [26] evaluated pulmonary phage therapy using a
ﬂuorescently labelled P. aeruginosa strain (to monitor in real-time the
spatial and temporal development of infection) in an acute mouse lung
infection model. The infectious dose was 107 CFU/mouse. In preventive
experiments, phages were given intranasally 24 h before infection. Page
lysates were simply puriﬁed using caesium chloride ultracentrifugation
and then suspended in phosphate buﬀered saline. Untreated mice died
within 48 h of infection. Mice treated with a phage to bacterium ratio of
1:10 died within 5 days after infection. Mice treated with a higher
phage to bacterium ratio 1:1 (80–100%) and 10:1 (100%) survived
until the end of the experiment (12 days post-infection). Subsequent
experiments were carried out using the higher phage dose i.e. phage to
bacterium ratio of 10:1. Phages were administered 2 h post-infection.
Within 6 h post-infection diﬀerences were observed in the amount of
luminescent bacteria in the lungs of the infected mice suggesting rapid
killing by the phage. After 24 h untreated mice were either dead or
showed high levels of luminescence whereas phage treated mice
showed no or weak spots of light with tissue cultures showing bacterial
load of 108 CFU/ml in untreated mice versus 102 CFU/ml in phage
treated mice at 24 h post-infection. Phage concentrations in bronchiolar
lavage ﬂuid were lower in uninfected controls (106 PFU/ml) versus
infected and phage treated mice (107 PFU/ml) indicating phage am-
pliﬁcation within the infected lungs. Measurement of inﬂammatory
cytokines IL-6 and TNF-alpha indicated attenuation of the host in-
ﬂammatory response due to phage treatment. Delaying phage treat-
ment by 2 h, 4 h and 6 h post-infection resulted in all mice surviving
after 24 h (treated with phage 2 h post-infection) but only 75% of mice
surviving following phage treatment 4 h and 6 h post-infection. At 72 h
post-infection survival was as follows 100% (2 h delay), 75% (4 h
delay) and 25% (6 h delay). Phages were seen to remain eﬀective in
mice 24 h following treatment. Infection of mice 24 h post-phage
treatment (intranasal administration of 108 phages/mouse: 107 CFU/
mouse) resulted in 100% of mice surviving 16 days post-infection
whereas all untreated mice had died. Non-invasive bioluminescence
data suggested that rapid bacterial replication kinetics was an im-
portant factor in arresting infection by early administration of phage
when the bacteria were also highly susceptible to phage infection. High
dose of phages administered early during the onset of infection rapidly
reduced bacterial numbers and the associated inﬂammatory response in
the host.
Alemayehu et al. [27] compared phage therapy eﬃcacy in a murine
model using both mucoid and non-mucoid P. aeruginosa strains isolated
from CF patients. Lungs of 6- to 8-week old mice were infected in-
tranasally with lux-tagged Pseudomonas (dose 106 CFU/mouse). 2 h
following infection a binary mixture of phage (podovirus and myovirus)
was delivered intranasally at a dose of 107 PFU/mouse. Phages were
eﬀective in reducing considerably the amount of bacteria associated
bioluminescence in the ﬁrst 6 h period post-infection.
Morello et al. [28] evaluated the eﬃcacy of phage treatment in a
mouse lung-infection model (a dose of 106 CFU/mouse resulted in an-
imal death 2 days following infection) against a multidrug resistant P.
aeruginosa mucoid strain isolated from a cystic ﬁbrosis patient. Within
20 h post-infection, bacteria had multiplied in the lungs by 2-log
compared with the initial dose (found in broncho-alveolar lavages). A
dose dependent curative eﬀect was observed when phage (dose
106 PFU/mouse or 107 PFU/mouse was given intranasally 2 h post-in-
fection). 20 h post-infection bacteria were detected in macrophages,
alveolae and extracellular spaces of lungs from untreated animals.
Phage treatment resulted in lower concentrations of bacteria, high
concentrations of phage (suggesting in situ ampliﬁcation) and low
concentration of markers of host immune response (cytokines and lac-
tate dehydrogenase) with histological examination of lung tissue sam-
ples indicating less severe damage to lung tissues for the phage treated
mice. Uninfected mice given phage intranasally cleared these at the rate
of 0.5 log/day. Phage given 4 days prior to mice being given an in-
fective dose of bacteria needed high preventive phage doses (108 PFU/
mouse) to achieve 100% survival.
The use of bacteriophage as a therapeutic strategy to ﬁght K.
pneumoniae infection has previously been tested; a murine model of
infection could be cleared [32]. However, in this study (as in other
animal studies reviewed above), clearance of infection only occurred
when bacteriophage were administered immediately after K. pneumo-
niae infection which limits the potential of phage therapy for clinical
use.
Singla et al. [31] used liposome encapsulation of the lytic K. pneu-
moniae bacteriophage (belonging to the Podoviridae family). They in-
vestigated treatment eﬃcacy of liposome-encapsulated phage com-
pared with free phage, to treat established K. pneumoniae infection in a
murine pneumonia model. Delay in phage treatment administered via
intraperitoneal injection (6 h, 24 h and 48 h) post-intranasal adminis-
tration of K. pneumonia was investigated. Free phage administration 6 h
post-administration of K. pneumonia was shown to result in complete
elimination of K. pneumonia from lung samples (this was not the case for
the 24 h (~2 log reduction in CFU noted) and 48 h (CFU levels similar
to untreated positive controls) treated animals) delay is phage treat-
ments. Phages were observed in the vascular and perivascular areas and
along alveolar septa; similar results were reported by other researchers
[42]. Phages were observed in lungs for longer (up to ~3–4 days) for
animals infected with K. pneumonia compared with negative controls.
Phage ampliﬁcation was noted in infected animals treated with free
phage. Animals treated with liposome encapsulated phage 6 h (infec-
tion cleared in 24 h post-treatment), 24 h (infection cleared in 24 h
post-treatment), 48 h (reduction in CFU) and 72 h (reduction in CFU)
after K. pneumonia infection showed variable levels of eﬃcacy of
treatment. Earlier treatment was better than delaying treatment 48 h or
72 h. In the K. pneumonia mouse infection model, bacterial concentra-
tions in control animals (untreated) were seen to peak at day 3 and fell
signiﬁcantly by day 5. Phage ampliﬁcation in lung samples was noted
for phage encapsulated liposome treated animals. Liposome entrapped
phage persisted in lungs for 5 days post-treatment. Prophylactic phage
treatment (3 h, 6 h and 24 h prior to intranasal K. pneumonia infection)
was studied [31]. No signiﬁcant therapeutic eﬀect was observed for
mice treated with free phage 24 h prior to infection. The 3 h and 6 h
treatment resulted in absence of infection. For phage encapsulated in
liposomes no infection developed when mice were treated 6 h, 24 h and
48 h prior to administration of infection suggesting encapsulation had a
beneﬁcial prophylactic therapeutic eﬀect due to retention of the phage
at therapeutic concentrations in the lung.
Singla et al. [31] showed evidence of reduction in levels of pro-
inﬂammatory cytokines IL-6 and TNF-α with free phage treatment (0 h
and 6 h prior to intranasal bacterial inoculation) and with liposome
treated animals (24 h and 48 h prior to intranasal bacterial inocula-
tion). Debarbieux et al. [26] showed reduction in host inﬂammatory
response due to reduction in the number of bacteria upon phage
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treatment.
Although the majority of K. pneumoniae bacilli during infection are
thought to be extracellular, it is recognised that K. pneumoniae can
survive within macrophages and epithelial cells [93,94]. Liposome
encapsulation may enhance access of phage to intracellular K. pneu-
monia. Using an ex vivo model of cultured murine peritoneal macro-
phages infected with K. pneumonia, Singla et al. [95] showed that ca-
tionic liposome encapsulated phage were able to kill greater numbers
(~95%) of intracellular K. pneumonia compared with free phage
(~20%). A potential limitation of phage therapy for treatment of in-
fection is the development of phage-neutralising antibodies which may
result in reduction of the concentration of phage at the site of infection
or in systemic circulation [30]. Singla et al. [95] demonstrated using ex
vivo experiments that liposome encapsulation was eﬀective at com-
pletely protecting K. pneumonia phage from the neutralising eﬀect of
murine antibodies, whereas free phages were inactivated by serum
antibodies raised against the phage in mice. Liposome encapsulated
phage were able to inactivate K. pneumonia following 3 h exposure to
mouse serum containing antibodies.
3.6. Phage therapy for chronic infections
Results of animal studies (discussed above) relate to acute, rapidly
progressive infections. In chronic infections, bacterial populations may
have a greater diversity of bacterial strains as polymicrobial colonies
encased within bioﬁlms with signiﬁcant bacterial populations main-
tained over long periods of time, years even decades. Although a
measureable speciﬁc immune response to the presence of the antigens
expressed by the infecting bacteria may be present, however, on its
own, the host may be unable to clear the infection.
Alemayehu et al. [27] investigated the ability of phage to penetrate
and kill Pseudomonas cells growing as bioﬁlms on the surface of a layer
of human lung cystic ﬁbrosis bronchial epithelial cells. Phage applied to
24 h old bioﬁlms (bacteria concentration ~ 107 CFU/well; phage do-
se ~ 108 PFU/well) were able to increase phage numbers by replicating
in situ whilst killing the resident Pseudomonas (2-log reduction in ob-
served bioluminescence and 3- to 4-log reduction in cell concentration
after 24 h incubation of phage with cells). It took longer to clear
Pseudomonas grown in bioﬁlms in comparison with planktonic cells in
the lung model. Singla et al. [95] evaluated phage activity against
young (4 day old) and more mature (7 day old) K. pneumonia bioﬁlms.
Both free phage and liposome encapsulated phage showed similar levels
of antimicrobial activity (~2 log reduction in CFUs) in the 4 day old
bioﬁlm model compared with the antibiotic amikacin. For 7 day old
bioﬁlms the eﬀect was less marked (~1 log reduction).
Cocktails of phage covering multiple species and having the correct
host range for diﬀerent strains may be needed to facilitate clearance of
chronic infections. Examples of such chronic infections include infec-
tions in cystic ﬁbrosis (P. aeruginosa) and tuberculosis (M. tuberculosis).
Having suitably diagnosed the polymicrobial constitution of the infec-
tion causing bacteria, tailored phage formulations would need to be
prepared and administered. Phage banks with well characterised phage
lines with long shelf life would be needed in order to prepare such
formulated phage cocktails and supplied for clinical use. The challenge
here is delivery of precise concentrations of formulated phage cocktails
at the site of infection e.g. for cystic ﬁbrosis, which may require the
phage to penetrate bioﬁlms to gain access to the bacteria. Furthermore
the phage would need to be phagocytosed into macrophages to target
M. tuberculosis cells present in granulomas which poses an additional
challenge.
3.7. Phage therapy case studies with humans and recent clinical trials
There are relatively few recent published randomised control trial
studies on the therapeutic use of phage involving humans. Typically
these tend to be case studies [96] however, recently two small rando-
mised controlled trials have been undertaken [35,97]. The formulations
used for these trials tend to be simple phage lysates that have been
puriﬁed using crude laboratory methods including centrifugation, mi-
croﬁltration, ultracentrifugation and in some instances endotoxin re-
moval through aﬃnity chromatography [98]. Phage cocktails used for
the trials were simple suspensions in buﬀer without microencapsula-
tion. The titre of phage s used was typically low and reliant on in situ
ampliﬁcation which may have resulted in therapy failure in at least one
of the studies [35].
Wright et al. [97] conducted a small (24 patients) randomised (two
groups of 12), double blind Phase I/II clinical trial to evaluate the safety
and eﬃcacy of a therapeutic phage preparation against chronic otitis
due to antibiotic resistant Pseudomonas aeruginosa infection. Each
0.2 ml dose contained 105 PFU/ml each of six bacteriophages sus-
pended in 10% glycerol in phosphate-buﬀered saline and was applied to
the infected ear using a standard 1 ml syringe equipped with a 27 gauge
spinal needle. Patients re-visited the clinic on 7, 21 and 42 days fol-
lowing treatment. Patient inclusion criteria included checking that the
P. aeruginosa strain causing infection was susceptible to at least one
phage in the therapeutic cocktail. Bacteriophage ampliﬁcation (~2 log)
was noted for bacteriophages in human subjects under trial conditions
[97]. There were no reported side eﬀects and no evidence of local or
systemic toxicity due to phage therapy. Phage therapy was shown to
result in a modest reduction (from the baseline) in median P. aeruginosa
counts. Results were not overwhelmingly conclusive. In cases where
infection was treated phage counts decreased to below the limit of
detection. At day 42, 3 out of 12 patients in both the phage therapy
group and the placebo group had levels of P. aeruginosa below the limit
of detection. High levels of P. aeruginosa were present in patients
~109 CFU/g.
A recent randomised phage therapy trial to reduce E. coli associated
diarrhoea in children (6–24 month old males) failed to improve diar-
rhoea outcomes. This was attributed to low intestinal E. coli con-
centration resulting in lack of signiﬁcant phage ampliﬁcation in vivo
[35]. Half of the patients contained phage susceptible E. coli in stool
samples however, the stool CFU titres were low (median titre 105 CFU/
g stool). Phage-bacteria pharmacodynamics dictates that conditions
where there is a low in situ bacterial concentration are not conducive to
signiﬁcant phage ampliﬁcation. Phage cocktails used in the study were
given orally without antacid and were not protected from the stomach
acidity by encapsulation hence phage titres reaching the site of infec-
tion may have been low. Rapid elimination of the phage from the host
may also have further lowered the eﬃcacy of the treatment.
Fish et al. [96] recently published results of six case series where
bacteriophage treatment of intransigent diabetic toe ulcers was suc-
cessful. The study used a commercially available (Eliava Bioprepara-
tion, Tbilisi, Georgia) single lytic phage Sb-1 (broad host range against
S. aureus) in sterile solution (10 ml per vial containing ~107–108 PFU/
ml). Treatment involved standard wound care, including weekly soft
tissue debridement if necessary [96]. Phage preparation was applied
topically by dripping the phage solution into the wound cavity; gauze
soaked with phage solution (0.1–0.5 ml depending on ulcer volume)
was packed into the cavity and the wound was wrapped with dry gauze.
The actual dose given was variable depending on the size of the toe
ulcer. The patient was instructed to leave the gauze in place for 48 h.
The protocol was repeated weekly in a hospital-based wound clinic
setting until the ulcer became too small to pack. All six cases reported
healed with an average time to heal of ~6 weeks.
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Merabishvili et al. [98] prepared a well-deﬁned cocktail (designated
BFC-1) of lytic phage (containing a mixture of three broad host range
lytic phages; two Myoviridae (against P. aeruginosa and S. aureus) and
one Podoviridae (against P. aeruginosa)) designed for treatment of P.
aeruginosa and S. aureus infections in burn wound patients as part of a
pilot human clinical study. The cocktail contained 109 PFU/ml of each
bacteriophage applied (application by spraying using a syringe with a
spray adapter ﬁtted at the end) in doses of 1 ml/50 cm2 wound bed with
the assumption that this would result in a ratio of phage to bacterium of
100:1. The cocktail formulation consisted of endotoxin free phage
(pyrogenicity evaluated using a rabbit animal model) suspended in
physiological buﬀer and stored at 2–8 °C in 3 ml ‘single use only’ vials.
Stored at 4 °C, the phage suspension titre remained stable over
12 months. A safety trial on infected burn wounds of eight patients had
shown no adverse events following application. No eﬃcacy data was
reported in the paper. However, a recent paper [99] presented results
from the application of BFC-1 cocktail on colonized burn wounds in a
small clinical trial (nine acute burn wound patients, 10 applications).
Punch biopsies were taken to determine bacterial species identiﬁcation
and antibiotic susceptibility tests. 1 ml of the BFC-1 solution was ap-
plied per 50 cm2 of burn wound area. The other half received standard
treatment protocols. Patients also received systemic antibiotic treat-
ment. Following BFC-1 treatment, the wound was covered with dres-
sings, gauze and bandages according to standard treatment protocols.
2–5 h later, the burn wound was uncovered and two biopsies taken next
to (within 2 cm) of the previous ones. Bacterial load determination of
the biopsies was undertaken. Despite initial indications of wound co-
lonization or infection, bacterial cultures taken before and after treat-
ment showed low levels of bacteria (in 8/10 applications). In all cases
bacterial load remained unchanged after BFC-1 applications as well as
after standard treatment. The low bacterial load in the wound was at-
tributed to topical and systemic antibiotic treatment of patients prior to
enrolment of the patients in the study (which took 7 days from initial
assessment of colonization/infection with target pathogen). Rose et al.
[99] found that the sprayed BFC-1 solution had a tendency to run oﬀ
the burn wound. Better formulation e.g. as a gel or part of a dressing
(e.g. with controlled release properties) was suggested for future trials.
3.8. Summary
For phage therapy to work, bacteriophage concentrations at the site
of infection must be suﬃciently high for signiﬁcant in situ phage am-
pliﬁcation to occur and as a result reduce the rate of replication of the
infecting population of bacteria. The phages need to be delivered to the
site of infection and they need to have access to replicating bacteria
susceptible to phage infection. Even when susceptible bacterial con-
centrations are high at the site of infection, delivery of low con-
centrations of phage may not be suﬃcient to increase phage con-
centration rapidly enough to achieve rapid killing of bacteria. Self-
ampliﬁcation will not occur when concentrations of bacteria are low
[8]. In vivo reduction in phage concentration due to the host immune
response or other mechanisms also needs consideration. Under these
conditions, steady or frequent delivery of high concentrations of phage
may be needed for successful phage therapy. Phage resistant popula-
tions are highly likely and require use of a number of phage strains that
bind to diﬀerent receptors thereby killing the mutant bacteria. Use of
diﬀerent phage strains for therapeutic use requires careful formulation
of phages to retain phage stability such that viable phages at a suﬃ-
ciently high concentration are present at the time of use. Rational de-
sign of micro- and nanocapsules loaded with precise dose of en-
capsulated phage in stimuli responsive controlled release systems could
be engineered to do this.
4. Bacteriophage encapsulation
Developing formulations that incorporate bacteriophage for ther-
apeutic applications requires an appreciation of the chemical and
physical stresses phage may encounter both during processing as well as
during storage once formulated. Phage inactivation and long term re-
duction in phage titre upon storage is highly undesirable. The physical
and chemical properties of the formulation need careful consideration
when selecting a technique for encapsulation. Accurate loading of
phage per particle requires particle monodispersity which is rarely
achieved in practice however, some techniques are considerably better
than others (discussed below). The particle morphology should be
without deformities and the particles shouldn't aggregate or un-
controllably fuse together with material in the surrounding environ-
ment. A polymer or lipid may be used to coat an existing structure
containing the phage, for example Murthy and Engelhardt [82] sprayed
phage on dried skimmed milk and then encapsulated them in a lipid
coating. Alternatively, phage may be incorporated in the formulation
within the droplet which upon drying or crosslinking results in phage
entrapment in the particle core. Depending on the technique used,
polymer gelling may be part of the technique or it may be a process
occurring downstream. There are many techniques and processes that
may be used for stabilising, immobilising and encapsulating phage. The
most common methods are spray-drying, spray freeze drying, freeze
drying, extrusion dripping methods, emulsion and polymerisation
techniques. The literature focusing on phage encapsulation, formula-
tion and storage stability is reviewed below and summary information
is presented in Tables 2–4.
4.1. Formulation of bacteriophage for preservation and storage
Phages are protein structures and they are therefore susceptible to
factors known to denature proteins; these include exposure to organic
solvents [100,101], high temperatures [102], pH [102,103], ionic
strength [103], and interfacial eﬀects. Additionally, mechanical stresses
during formulation or encapsulation including shear stresses during
mixing and agitation, atomisation during spraying [104] and, desicca-
tion stresses during drying [105], need careful consideration. Drying
and lyophilization of bacteriophage with suitable carriers and bulking
agents to improve storage life have been the focus of numerous studies
(Table 2). A number of encapsulation techniques (reviewed further on)
have been used, followed by drying [75] or incorporating solvent
evaporation (e.g. during electrospinning, [106]) to improve phage
storage. One of the most common and successful modes of long-term
preservation of bacteriophage is storage at 4 °C in Trypticase Soy Agar
and Brain Heart Infusion broth whereas storage at −80 °C requires
50% glycerol as a cryoprotectant [107] or freeze drying with excipients
(e.g. sucrose or trehalose) as lyophilization and cryoprotectants
[108,109]. Ackermann [109] observed that phage titres for one of the
largest collections of tailed phages typically tended to drop by 1 log
over the course of a year but then remained fairly stable (although there
were many individual variations).
Clark [107] working for the American Type Culture Collection (A-
TCC) evaluated storage stability of a wide variety of bacteriophages (16
in total) for long term preservation and distribution. Phage specimens
were treated and stored for two years at room temperature and at 4 °C
as (i) broth lysates; (ii) lysates diluted with 50% glycerol; (iii) satur-
ating ﬁlter paper with lysate and then drying; (iv) freeze dried by
mixing lysates with an equal volume of double strength skim milk
(routine practice at that time at the ATCC). Phage titres measured im-
mediately post-processing indicated that freeze drying resulted in a
signiﬁcant loss of titre (between 1 log and 2 log reduction). However,
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freeze drying did produce stable phage titres over the course of 2 years
when stored refrigerated. After two years, the titre of phage in the broth
lysates were found to be generally higher than those of glycerol or
freeze dried preparations. Thermally dried preparations generally did
not prove satisfactory. Preparations stored at 4 °C showed higher titres
than those kept at room temperature. All titres declined with time re-
gardless of the conditions of preservation.
4.1.1. Eﬀect of thermal and environmental stresses on phage stability
Phage may show diﬀerent susceptibility to ingredients used in for-
mulations. Knezevic et al. [103] examined the eﬀects of environmental
factors on adsorption and inactivation of four P. aeruginosa phages (one
Podoviridae (designated δ) and three Siphoviridae phages (designated J-
1, σ-1 and 001A). Factors investigated included temperature (range
7–44 °C, exposure for 30 min in SM buﬀer), pH (pH 1.5–pH 9, at 37 °C
for 30 min), phage neutralisation by exposure to carbohydrates and
amino acids (potential phage receptor constituents; incubation at 37 °C
for 30 min in SM buﬀer containing either glucose, rhamnose, mannose,
galactose, glucosamine, glutamine or alanine), exposure to exopoly-
saccharides and lipopolysaccharides, silver nitrate (e.g. for combination
therapy with phage), povidone-iodine (for combination therapy) and
exposure to serum of rats. All phage were completely inactivated after
30 min exposure at pH 1.5. Maximum viability was observed at pH 7.
Signiﬁcant diﬀerences in susceptibility for the phage were observed at
pH 3, 5 and 9. Phages σ-1 and δ were found to be less susceptible to low
pH than J-1 and 001A. Survival at pH 9 was higher than at pH 5. Phage
δ was considerably neutralised by glucose, rhamnose, glucosamine,
mannose and alanine. None of the phage survived at working silver
nitrate concentrations of 0.3%. Phages δ and 001A were highly sensi-
tive to povidone-iodine; exposure for 30 min to even the lowest con-
centration 0.5% completely inactivated them. For phages σ-1 and J-1
the PhI50 (i.e. concentration to achieve a 50% reduction in titre) con-
centration values were ~4%.
Briers et al. [102] evaluated the stability of the structural pepti-
doglycan hydrolase gp181 of the P. aeruginosa Myoviridae bacter-
iophage ϕKZ to temperature (range 25–90 °C), ionic strength
(20–320 mM) and pH (5–8). The protein is supposed to degrade the
peptidoglycan layer locally during the infection process. Gradual loss of
enzymatic activity due to thermal inactivation was observed from 100%
activity at 25 °C down to 0% at 70 °C when exposed for 60 min and
down to< 20% activity when exposed for 10 min to 90 °C. Optimal
enzymatic activity at 25 °C was observed at pH 6.2 and ionic strength
140 mM with variation in pH and ionic strength in either direction
resulting in loss of activity.
4.2. Freeze drying of bacteriophage for storage and encapsulation
Freeze drying (lyophilization) is routinely used in the pharmaceu-
tical industry [110] to dry proteins, vaccines, peptides or colloidal
carriers such as liposomes, nanoparticles and nanoemulsions [111].
Freeze drying is typically done from solution and involves a freezing
step followed by a drying step. During the freezing step, the phage
containing solution is cooled and ice crystals of pure water form re-
sulting in concentration of the remaining liquid. This typically results in
an increase in viscosity as well as osmolarity of the concentrated so-
lution which inhibits further crystallization and eventually results in a
frozen amorphous/crystalline phase. Preventing aggregation of bac-
teriophage and inactivation due to high osmotic pressure changes needs
careful consideration here. At the end of the freezing stage, drying
begins as a result of switching on a very low temperature condenser
which draws water from the sample over time. A vacuum is also pulled
to remove air which slows mass transfer to the condenser. A primary
drying stage results in direct sublimation of the ice crystals, and
remaining adsorbed water is removed in a secondary drying phase. In
the freeze-dried state, the rate constants of most chemical and physical
degradation reactions are dramatically reduced thereby permitting long
term storage under refrigerated or ambient temperatures (25 °C). Tra-
ditional freeze drying is a slow process since the lyophilization is car-
ried out at temperatures below the glass transition temperature of the
maximally freeze-concentrated bacteriophage-excipient solution (Tg′)
and below the collapse temperature (Tc) of the sample thereby yielding
a porous material with microstructure that is conducive for drying.
Freeze dried material typically results in a cake that needs further
processing e.g. milling to achieve ﬁne particles suitable for loading in
dry powder inhalers (DPI) [112].
A brief summary of the main issues surrounding the freeze drying of
phage is now given. Papers on phage and virus freeze drying have
mainly focused on evaluation of formulations in order to stabilise phage
for storage [105,109,113–115]. A number of papers have shown that
addition of amino acids (e.g. sodium glutamate [113]), peptides (e.g.
peptone [108]) and proteins (casein and lactoferrin [116]) to the for-
mulation improves phage viability upon freeze drying and following
rehydration (Table 2). Literature suggests that disaccharides e.g. lactose
[116], sucrose [105,114,115,117] and trehalose [77,104,105,114,118]
improve phage survival during freezing as well as subsequent lyophi-
lization. Osmotic damage is an important factor that reduces phage
surviving the freeze drying process [108]. This includes hydration
stresses which may be ameliorated through addition of sugars to the
hydration medium [119], something often overlooked in recent studies
that use simple buﬀer or saline for rehydrating freeze dried samples
[105,114,120]. A number of papers have shown that the concentration
of sucrose in the formulation aﬀects phage viability during freeze
drying and subsequent rehydration [105,114], although diﬀerent
phages would appear to prefer either high or low concentrations. Rapid
rates of freezing at relatively low temperatures (<−20 °C) have been
found to result in better phage survival compared with slow freezing.
This has been attributed to having less time for osmotic damage to
occur [108].
A detailed listing of literature studies is provided in Table 2 and
more detailed commentaries on some selected papers are now given as
follows.
Engel et al. [113] investigated the storage stability of mycobacter-
iophages using freeze drying. The eﬀect of various cryoprotectants and
lyoprotectants at varying phage titre (104, 105 and 109 PFU/ml, for
phage BK1) was investigated including sodium glutamate (with and
without gelatine), gelatine, peptone (with and without sorbitol), dex-
tran (with glucose), calf serum and skim milk. 53 diﬀerent myco-
bacteriophages were ﬁnally tested using sodium glutamate (5 wt% with
0.5 wt% gelatine). Storage of freeze dried phage at room temperature in
the dark for as long as 2.5 years resulted in only a modest change in
phage viability.
Puapermpoonsiri et al. [117] carried out a qualitative study evalu-
ating the eﬀect of sucrose, PEG and gelatine during freeze drying on
short term viability of S. aureus and P. aeruginosa bacteriophage over a
30 day period. Primary drying (freezing and sublimation of frozen
water at −30 °C for 1000 min) was followed by a secondary drying
cycle (at an elevated temperature of 25 °C for 6 h) to desorb adsorbed
water. The residual moisture content (4–6 wt%) of the freeze dried
powder was found to correlate with better phage viability; but due to
the qualitative nature of this work, it is diﬃcult to accurately assess the
magnitude of this eﬀect, which needs further exploration. Gelatine was
found to play no role in maintaining phage viability following lyophi-
lization. Control of the residual moisture content in the lyophilized
material was found to be important in order to balance chemical (re-
activity of amino acids) and physical stability (e.g. unfolding of tail
proteins) of bacteriophage resulting in loss of lytic activity. High
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concentrations of sucrose and PEG were needed to prevent collapse of
freeze dried cakes due to secondary drying at 25 °C. High concentra-
tions of additives (e.g. sucrose) lead to a decrease in phage titre with
better results at lower sucrose concentrations. After 30 days of storage
at 4 °C viable phage were still present. Dini and Urraza [105] in-
vestigated the eﬀect of buﬀer systems (PBS and SM), buﬀers with/
without skimmed milk and addition of disaccharides (sucrose or tre-
halose) on a Podovirus coliphage stability during freeze drying (at
−80 °C for 24 h) and storage. The coliphage freeze dried in SM buﬀer
gave the highest titre compared with skimmed milk and PBS respec-
tively. Addition of trehalose or sucrose to PBS did not improve phage
titre outcomes. This may have been due to hydration stresses due to
osmotic shock rather than the freeze drying process. Freeze dried
samples were rehydrated using a simple buﬀer rather than a buﬀer with
added sucrose to prevent osmotic shock. Addition of sucrose to PBS did
stabilise the phage titre upon storage for 120 days (at 4 °C) with phage
freeze dried in PBS alone showing a progressive decrease in phage titre
over 120 days of storage (~2.5 log loss compared with the initial lyo-
philized product). Addition of sucrose at low concentrations (0.1 M) in
SM buﬀer was found to result in a high phage titre post-freeze drying
(only a ~0.5 log drop in titre attributed to the drying step rather than
freezing step) with the titre remaining stable for up to 120 days upon
storage. Increasing the sucrose concentration in SM buﬀer to 0.3 M or
0.5 M resulted in a ~0.5 log lower titre compared with the 0.1 M su-
crose sample. Sucrose containing powders had a higher residual
moisture content, compared with samples dried using PBS or skimmed
milk. Only a small portion of the overall loss of phage titre (~0.3 log)
was attributed to the freezing step (for the 0.5 M sucrose-SM buﬀer
sample) with lyophilization accounting for the majority of the ~1.5 log
phage titre loss. Whether this could be attributed to the rehydration
step needs further exploration.
One of the only papers to look at rehydration was Cox et al. [119]
who looked at loss of phage viability arising from detachment of tails
from capsid heads due to rapid rehydration following freeze drying.
Slow rehydration of freeze dried phage by exposure to a controlled
humidity environment (100% RH at ambient temperature) for 60 min
followed by rehydration using broth or sucrose containing broth re-
sulted in signiﬁcantly higher phage titre. The eﬀect of hydration is one
area that deﬁnitely needs further exploration.
Merabishvili et al. [114] investigated the stability of a S. aureus
myovirus phage ISP after freeze drying. Diﬀerent formulations con-
taining two diﬀerent concentrations of phage titres (108 and 109 PFU/
ml) were prepared with diﬀerent excipients (each excipient at either
0.1 M or 0.5 M concentration: sucrose, trehalose, mannitol, glycine, and
polyvinylpyrrolidone (PVP) and PEG 6000 at 1% and 5%). Primary
drying was carried out at −30 °C whereas for secondary drying, the
temperature was gradually increased to 25 °C over a period of ~10 h
followed by isothermal drying. Some of the excipients (PVP, mannitol
and PEG 6000) proved to be unsuccessful. PVP was found to inactivate
the phage even before freezing. Complete inactivation of phage ISP
after lyophilization was observed using glycine as excipient (glycine
crystallizes during freezing). Complete loss of phage ISP activity using
the sugar alcohol mannitol at 0.1 M was observed with a 4 log titre
reduction using 0.5 M concentration. The phage titre thereafter re-
mained stable over a 27 month period with a 2 log reduction after
37 months of storage. Phage ISP titre in PEG 6000 showed a 1.8 log (1%
PEG) and 5 log (5% PEG) reduction following lyophilization. After
37 months of storage, further loss of titre was 3 log (1% PEG) and
1.7 log (5% PEG). High concentrations (0.5 M) of trehalose and sucrose
were found to be the most eﬀective stabilisers for phage ISP. A 1 log loss
in phage titre was observed immediately after lyophilization with a
further 1 log loss following 37 months of storage. Diﬀerent concentra-
tions of trehalose and sucrose (0.3 M, 0.5 M, 0.8 M and 1.0 M) were
studied further. Phage ISP freeze dried from 0.8 M and 1.0 M sugar
solutions showed the smallest titre reduction immediately after drying
(~0.5 log). Over the next 27 months of storage phage ISP titre
remained stable (variability within ~1 log, measured at time period 3,
7, 12 and 27 months). Phage ISP stability was also recorded for phage
stored in LB broth (1 log reduction) and 0.9% NaCl (~2 log reduction)
over the same period (after 37 months) stored at 4 °C. Malenovská
[115] also reported good results with sucrose in combination with ge-
latine during lyophilization of structurally diﬀerent animal viruses. It is
noteworthy that a commercially available freeze dried phage cocktail
preparation contains sucrose and gelatine [121].
Golshahi et al. [116] determined the feasibility of preparing stable
freeze dried formulations of B. cepacia and P. aeruginosa phage for re-
spiratory delivery. A 2 log reduction in phage titre was achieved fol-
lowing freeze drying in a formulation of lactose/lactoferrin (60:40 w/
w). Freeze dried phage titre remained stable over a 3 month storage
period at 4 °C and 22 °C. Addition of lactoferrin resulted in powder that
did not require milling to make it respirable (size < 5 μm) with
~30 wt% of powder available in the free particle fraction (FPF) upon
aerosolization.
4.2.1. Freeze drying of encapsulated phage
A number of papers have looked at freeze drying phage in-
corporated in polymer matrices [77,100,118,121,122]. Pua-
permpoonsiri et al. [100] lyophilized microencapsulated S. aureus and
P. aeruginosa phage (dispersed in a salt buﬀer with gelatine) in PLGA
(poly(lactic-co-glycolic acid)). The microspheres were frozen in liquid
nitrogen followed by lyophilization. All phage viability was lost after
7 days of storage regardless of storage temperature. Loss of phage via-
bility was attributed to the use of an organic solvent in the emulsiﬁ-
cation process (discussed later). Alfadhel et al. [123] used freeze drying
as part of the encapsulation process. S. aureus phage containing nasal
inserts were prepared by freeze drying (freezing at −30 °C and drying
at 10 °C) phage formulations containing hydroxypropyl methylcellulose
(HPMC) as the encapsulating polymer. Freeze drying of phages for-
mulated in the polymer solution resulted in ~1 log drop in titre im-
mediately after lyophilization and between 3 and 4 log reduction over a
year of storage at 4 °C. Addition of mannitol or increasing the HPMC
concentration was not found to improve phage stability during storage.
Dai et al. [118] undertook encapsulation of E. coli phage in water
soluble polyvinylpyrrolidone (PVP) nanoﬁbers prepared using electro-
spinning. Phage containing PVP solutions (with and without trehalose
in SM buﬀer) were frozen in liquid nitrogen and then freeze dried
(drying conditions not given). Immediately after drying the PVP and
PVP-trehalose solutions showed no signiﬁcant drop in phage titre.
However, after 8 weeks of storage at room temperature (humidity <
40%) the PVP sample showed a 3 log drop in titre whereas the PVP-
trehalose sample showed no signiﬁcant titre drop. Korehei and Kadla
[106] encapsulated E. coli phage using emulsion electrospinning and
co-axial electrospinning. In emulsion electrospinning, the phages were
pre-encapsulated in alginate nanoparticles which were suspended in
polyethylene oxide (PEO)/chloroform solution for electrospinning. In
co-axial electrospinning the aqueous phage suspension remained in the
core of the ﬁber whereas the shell was made from polyethylene oxide
(PEO). The phage containing ﬁbers were freeze dried (details not
given). Fibers prepared using co-axial electrospinning were stored at
20 °C, 4 °C and −20 °C for up to 4 weeks. High phage titre was ob-
served immediately after freeze drying of ﬁbers prepared using emul-
sion (106 PFU/ml) and co-axial (108 PFU/ml) electrospinning. Over
4 weeks of storage the co-axial ﬁbers showed no loss of phage titre
when stored at −20 °C and 4 °C whereas a signiﬁcant drop in tire
(> 6 log reduction) was observed for the samples stored at 20 °C.
Recently Colom et al. [77] showed promising freeze drying results
for trehalose containing liposomes with encapsulated S. enterica phage.
Lyophilization resulted in a modest drop (< 1 log) in phage titre for the
liposome encapsulated phages. Trehalose containing liposomes showed
no loss of phage titre when stored at 4 °C in 10 mM MgSO4 buﬀer
(pH 6.1) for a period of 3 months.
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Table 2
Summary of studies looking at eﬀects of formulation, drying and storage on phage viability.
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[107] Ec M Pa Sa 12 B L 24
B Gl L
B P FD
B P FP
[104] Pa W T M Le SF NA
W T M Le SD
[113] M B Ge A FD 30
B P FD
B O FD
[108] Cu B A FD 3
B A S FD
[119] Ec B S FD NA
[109] Ec Pa Sa Vc
>
40
0 B L NA LT
B Gl L
[105] Ec Bu FD 4
Bu S FD
[114] Sa B S FD 37
B T FD
B PV
B A FD
Sa L
B L
B M FD
B O FD
[123] Sa Bu Ge M (FD) 12 -
Bu Ge M O (FD)
-
[118] Ec Bu T PV FD 2 
W T PV FD
Bu PV FD
W PV FD
[106] Ec Bu (FD) 1 
[120] Pa W T Le SD 12 /
M Le SD /
[100] Pa Sa Bu (FD) 0.25
[117] Pa Sa Bu S FD 1
Bu FD
Bu G FD
Bu O FD
[75] Ec Bu (SD) 12
[128] Pa Sa Bu La (SD)
-
N/A
Bu T (SD)
-
Bu O (SD)
-
[132] Pa Sa Bu T SD N/A 12 -
-
[77] Se W T (FD) 3
[131] Bc Pa Bu P T Le O SD 3
[116] Bc Pa W P La FD 3
[157] Sa Bu P O (AD)
-
0.5
Sa Bu P O (L) 1.5
Intensity of shading diﬀerentiates vertical sections of the table.
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4.2.2. Spray freeze drying of bacteriophage
Spray freeze drying may oﬀer the possibility of a single step process
to produce bacteriophage loaded porous powders with controlled par-
ticle-size distribution without subjecting the phage to high thermal
stresses encountered during conventional spray drying (discussed
below).
Leung et al. [104] recently spray freeze dried (using an ultrasonic
nozzle to atomise the solution) a P. aeruginosa podovirus (PEV2) by
spraying the phage solution (formulations containing diﬀerent con-
centrations of trehalose, leucine and mannitol in combination) directly
into a dewar of liquid nitrogen; the frozen droplets were subsequently
lyophilized (primary drying at−30 °C for 24 h and secondary drying at
25 °C for 48 h) in a conventional freeze dryer. The ultrasonic nozzle
employed high frequency vibration (48 kHz) to produce ﬁne droplets; a
signiﬁcant 2 log reduction in phage titre was noted just due to the ul-
trasonic spraying process itself (without freeze drying). The sprayed
droplets froze immediately upon immersion in liquid nitrogen. Sub-
sequent lyophilization resulted in highly porous dry powder (mean
geometric particle diameter ~ 30 μm corresponding to the droplet size
generated by the ultrasonic nozzle). Particles with high trehalose con-
tent (60%) were found to be highly hygroscopic and collapsed during
storage whilst particles with lower trehalose content (40%) retained
their porous structure (examined using SEM). The higher trehalose
containing particles adsorbed more water at lower relative humidity
values. Leung et al. [104] suggested handling and storage of powders
below 20% RH to avoid moisture related recrystallization of excipients
damaging encapsulated phage. The loss in phage titre post-atomisation
due to spray freeze drying was negligible; this suggested that phage
activity was preserved by the excipients during the freeze drying step as
well as the rehydration step. The high phage titre in the spray freeze
dried powders was attributed to rapid freezing of the droplets in liquid
nitrogen resulting in good distribution of the phage within the frozen
particles. Spray freeze dried powder with the higher trehalose content
also had the higher phage titre. The aerosol performance (using a
commercial DPI device, an Osmohaler™) of the freeze dried powders
showed a reasonable ﬁne particle fraction (size < 5 μm having 44%
phage dose ~ 104–105 PFU dose delivered) with high total recovery of
aerosolized viable phage dose (88%–97%).
4.3. Spray drying of bacteriophage for storage and encapsulation
Spray drying processes atomise a liquid containing dissolved solids,
converting it into a ﬁne mist which is contacted with a hot dry gas
(typically hot dry air) inside a drying chamber. Due to the high surface
area to volume ratio of the very small atomised droplets, the solvent
rapidly evaporates with each droplet forming a particle comprising the
non-volatile components (bacteriophage and excipients) along with a
small amount of residual moisture. The particles are separated from the
airstream exiting the dryer, and cyclones or bag ﬁlters are typically
used for this. Spray drying is a scalable industrial process technology
and is widely used to produce ﬁne powders for pharmaceutical appli-
cations including pulmonary delivery via dry powder inhalers (DPI)
[124]. Dry powders are favoured for respiratory drug delivery because
they show relatively long storage stability without requiring refrigera-
tion [125,126] and DPI are simple to use and do not require regular
cleaning and disinfection [127].
Phages have been shown not to be able to withstand high shear
stress for too long. The nebulization process has been shown to result in
loss of phage titre [104,128]. Phages are also sensitive to thermal
stresses and have been shown to partially lose activity at temperatures
higher than 60 °C [108,129]. Low spray drying temperatures (~40 °C
outlet air temperature) have been shown to result in higher phage titre
[120] with high loss of phage titre observed at higher temperatures
[104,128,130,131]. Literature on spray drying of phage suspensions
typically includes excipients in the formulation to protect the phage
from desiccation and thermal stress (Table 2). Upon spray drying, sugar
excipients form amorphous structures with high glass transition tem-
peratures (Tg), e.g. in their anhydrous amorphous form Tg of trehalose
is 115 °C and Tg for lactose is 108 °C. Below the glass transition tem-
perature, vitriﬁcation due to the excipient stabilises the encapsulated
bioactive agent and permits storage over long periods at ambient or
lower temperatures. Adsorption of moisture results in lowering of the
Tg and compounds that are hygroscopic e.g. lactose require handling
under controlled atmospheric conditions (low relative humidity) [131].
Refrigerated storage of spray dried powders at relative humidity ex-
ceeding 20% has been shown to result in loss of phage titre [120,132]
whereas samples stored at low humidity were stable. Trehalose is the
most frequently reported excipient used in the spray drying of phage
and it has been shown to result in spray dried powders with high phage
titre and good storage stability [104,120,131,132]. Trehalose has low
toxicity and has been shown to protect biological material including
proteins, probiotics and vaccines, against desiccation and thermal
stress. Crowe et al. [133] suggested that the eﬃcacy of trehalose as an
excipient in drying is partly due to its high glass transition temperature
at all water contents but also because trehalose binds residual water left
over from the drying process to form a dihydrate which might other-
wise participate in lowering the glass transition temperature to below
ambient [132]. Other excipients that have been used to improve the
dispersibility of spray dried phage containing powders include dextrans
[128], lactose (common excipient used for DPI powders; [112,128]),
glucose, sucrose, mannitol [104] and, leucine [104,131] (Table 2).
Reducing sugars such as lactose may be unsuitable excipients for bac-
teriophage [128]. Alternatives such as mannitol have been suggested in
the literature [134]. Phage spray drying studies using mannitol have
reported improved particle dispersion characteristics however, phage
viability results have been mixed [104,120]. Addition of proteins e.g.
casein in combination with trehalose have shown good results [131].
Refrigerated storage of spray dried powders was reported to yield
higher titres of phage during long term storage compared with storage
under ambient conditions [120]. Diﬀerent phage strains formulated and
spray dried under identical conditions showed signiﬁcant diﬀerences in
the resulting phage titre suggesting the need for individually for-
mulating each phage to be used in a phage cocktail [128,132]. A
number of studies have reported spray dried phage powders to have a
suitable mass median aerosolized diameter for pulmonary delivery of
phage to treat respiratory infections [104,128,131,132,135].
Stanford et al. [75] took a cocktail of 5 E. coli phage (as lysates)
which were added to an aqueous pH responsive methacrylate polymer
(Eudragit S100) containing an unspeciﬁed stabiliser, then spray dried
(co-current spray dryer ﬁtted with a rotary atomiser) into a powder
(with 4% moisture content). No drying conditions were reported in the
paper. The resulting encapsulated phages (described as Ephage) were
stored at 20 °C. Spray drying of the aqueous phage-polymer solution
resulted in a 1 log reduction in phage titre post-drying. Encapsulated
phages were shown to survive 20 min exposure to an aqueous solution
at pH 3. Storage at 20 °C for one year resulted in a decline in phage titre
of between 1 log and 3 log depending on the phage. Walbeck [130] in a
recent patent (assigned to Omnilytics, USA) reported a 7 log loss in
phage viability post-spray drying using E. coli O157:H7 speciﬁc phage
(the phage suspensions were unprocessed crude lysates including
phage, lysed bacteria and fermentation media, no excipients were
added, a rotary atomiser was used to generate the spray). The loss in
phage viability may be attributed to the high air inlet temperature
(range 200–220 °C) used which resulted in the dry phage powders being
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exposed to high air outlet temperatures (90–130 °C).
Vandenheuvel et al. [128] spray dried S. aureus and P. aeruginosa
phages using lactose, trehalose and dextran as excipients. Dextran was
used not only for its eﬀect as an excipient in the spray drying process; in
the treatment of respiratory infections it may prevent P. aeruginosa from
attaching to lung epithelial cells and may increase CF sputum clearance.
The eﬀect of atomisation air ﬂow rate and drying air inlet temperatures
were investigated (using inlet air temperatures of either 85 °C or
100 °C). At a relatively low inlet air temperature of 85 °C, the P. aeru-
ginosa podovirus was found to be more resistant to spray drying stresses
in comparison with a S. aureus myovirus. Lactose and dextran were
found to be unsuitable excipients, whereas phage viability results with
trehalose (4% wt) were more promising with< 0.5 log reduction for
the podovirus and a 2 log reduction for the myovirus. The eﬀect of air
inlet temperature was investigated further using trehalose only. The
viability of the myovirus was found to be strongly aﬀected by the higher
air temperature. At an air inlet temperature of 100 °C a ~5 log reduc-
tion in phage titre was observed in comparison with a ~3 log reduction
at 85 °C using the same air inlet ﬂow rate. The mean particle size (D50)
was between 2 and 6 μm. Increasing atomisation air ﬂow (which re-
duced particle size and would have increased atomisation stresses had a
mildly adverse eﬀect on phage tire). This paper showed that two dif-
ferent types of bacteriophage (a myovirus and podovirus) processed
under the same conditions show signiﬁcant diﬀerences in stability to
spray drying stresses and result in signiﬁcantly diﬀerent loss of titres.
The same group then assessed the storage stability (over 12 months)
of the spray dried S. aureus (myovirus) and P. aeruginosa (podovirus)
phage using trehalose as excipients [132]. They principally investigated
the eﬀect of relative humidity (RH 0% and RH 54%) and temperature
(0 °C and 25 °C). Within 3 months of storage, the S. aureus myovirus
titre fell by 2 log (4 °C, 0% RH) and 4 log (4 °C, 54% RH) respectively
but then stabilised thereafter. At 25 °C almost complete loss of phage
viability was observed (7 log) for both 0% RH and 54% RH samples
after 4 months of storage with a 2 log loss observed after the ﬁrst
month. The podovirus was more stable with< 1 log reduction over the
12 months for the 4 °C sample irrespective of the RH, and between 1 log
and 2 log reduction at 25 °C. Powder X-ray diﬀraction analysis (phage
free powders dried under identical conditions to the phage containing
powders) showed that spray dried trehalose powder was non-crystal-
line. Diﬀerential scanning calorimetry data showed that the spray dried
trehalose had a Tg between 116 °C and 117 °C i.e. the trehalose was in
an amorphous state suitable for phage vitriﬁcation. After 8 months of
storage at 54% RH, the presence of an endothermic peak between 86
and 91 °C on DSC scans indicated the presence of stable trehalose di-
hydrate crystals. Spray dried trehalose powder samples stored at 0% RH
did not show changes in DSC endotherms or XRD spectra. Trehalose is
known to protect bioactive agents from thermal and dehydration
stresses through structural and conformational stabilisation of proteins
by direct hydrogen bonding and the process of vitriﬁcation. Over time,
at 25 °C, phage titre dropped even where no crystallization of the
amorphous trehalose was observed.
Leung et al. [104] spray dried a P. aeruginosa phage (Podoviridae)
designated PEV2 focusing on making phage containing powder for
pulmonary delivery. The lytic podovirus (supplied by AmpliPhi Bios-
ciences, Australia) was used at a titre of 107 PFU/ml suspended in dilute
(2 wt% solids) aqueous mixtures of trehalose, mannitol and leucine
(respective ratios either 60:20:20 or 40:40:20). The formulations were
designed for use in dry powder inhalers (DPI), as leucine helps improve
the dispersibility of the powders by reducing cohesive interactions be-
tween particles. Mixing phage with excipients in solution resulted in a
~0.5 log titre reduction, which was attributed to changes in ionic
strength when the phage buﬀer was diluted in excipient solution. Leung
et al. [104] used a two ﬂuid nozzle for liquid atomisation which itself
resulted in a ~1 log loss in phage viability. The air inlet temperature
was 60 °C which resulted in low outlet temperatures of 40–45 °C. The
low outlet temperature was chosen to minimize thermal stress for the
phage. However, titres were lower (due to the drying process) than
recorded for spray freeze drying process reported using the same phage
and excipients in the same paper. Spray dried powders were collected
inside a relative humidity controlled chamber (RH < 20%) and stored
at 4 °C. Spray drying resulted in a further ~1.5 log drop in phage titre.
Leung et al. [120] further investigated the eﬀect of humidity (0%, 22%
and 60% RH) on long term storage (over 12 months) of spray dried
Pseudomonas aeruginosa phage (at 4 °C) dry powders containing dif-
ferent amounts of trehalose (40%, 60% and 80%). Storage in a low
humidity environment (0% and 22%) was found to result in no loss of
phage titre. High humidity (60% RH) resulted in complete loss of viable
phage after 3 months.
Matinkhoo et al. [131] spray dried Myoviridae bacteriophage for P.
aeruginosa (phiKZ and D3) and for B. cepacia (KS4-M and KS14) using
trehalose, leucine and casein (a mixture of four similar phosphoproteins
with MW between 19 kDa and 24 kDa) as excipients. Similar to Leung
et al. [120], leucine was added to improve the dispersibility of the
powder. Surfactants were added to some formulations to aid in the
dispersion of the bacteriophage in the feed solution [136]. A vibrating
mesh atomiser was used resulting in atomised droplet diameters around
7 μm. Mild spray drying conditions were used to provide a low outlet
temperature of between 40 °C–45 °C (air inlet temperature of 75 °C) and
an outlet relative humidity of< 7% RH. The spray dryer was housed in
a controlled humidity chamber with glove ports to allow collection of
and storage of powder without exposure to moisture. In vitro evaluation
of the deposition of the phage loaded spray dried powders was carried
out using an experimental idealized throat and lung system (Alberta
Idealized Throat attached to an Anderson cascade impactor) using a
commercially available DPI. Four formulations were tested: (i) Leucine
(77 wt%):trehalose (19 wt%) (LT); (ii) leucine (76 wt%):trehalose
(19 wt%):tyloxapol (2 wt%) (LTX); (iii) leucine (76 wt%):trehalose
(19 wt%):pluronic (2 wt%) (LTP); (iv) leucine (76 wt%):trehalose
(19 wt%):casein (2 wt%) (LTC). All powders had a well dispersed ap-
pearance. Small batches of material were produced for each formula-
tion; the manufacturing yield of the surfactant containing formulations
was signiﬁcantly higher (~80 wt%) compared with LT and LTC
(~60 wt%). Between 20 and 30 wt% of aerosolized dose (LTX, LTP and
LTC) did not reach the lung and was entrained in the mouth-throat
fraction. In all cases the total lung fraction exceeded 50 wt%. All
Myoviridae spray dried phages showed a titre loss of< 1 log. The for-
mulation containing trehalose, leucine and the milk protein casein was
found to be the best formulation. All the spray dried powder formula-
tions prepared by Matinkhoo et al. (2011) delivered> 50 wt% of dose
in the correct (< 5 μm) size range using the DPI. The LTC formulation
was found to most consistently deliver single phage doses and cocktails
of phage.
A number of in vitro studies have evaluated the use of nebulizers for
aerosolization of liquid phage formulations for pulmonary delivery.
Sahota et al. [137] carried out an in vitro study delivering an aerosol
containing two diﬀerent Pseudomonas aeruginosa bacteriophages
PELP20 and PELI40 (isolated from the commercially available
Pyophage and Intestiphage preparations from the Eliava Institute,
Tbilisi, Georgia). A commercial nebulizer was evaluated to deliver the
aerosolized phage dose into a cascade impactor (phage in the droplet
size range< 5 μm were deemed suitable for respiratory delivery); 12%
of the nominal dose was aerosolized with< 0.8% of dose found to be in
the correct size range for delivery to the lung. Golshahi et al. [138]
undertook a study where they employed two commercial nebulizers (a
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jet nebulizer (Pari LC star) and a vibrating mesh nebulizer (Pari eFlow))
and estimated that around 50% of nebulized Burkholderia cepacia phage
dose was in the droplet range (measured using Phase Doppler Anemo-
metry) that would result in deposition (estimated using mathematical
modelling) in either the tracheobronchial or alveolar region of the lung.
4.4. Drying bacteriophage on ﬁlter paper
A couple of early studies looked at stabilising phage by drying phage
suspensions by ﬁltering onto ﬁlter paper and then drying the ﬁlter
paper [107,139]. Prouty [139] investigated the long term storage of
bacteriophage of lactic acid streptococci by saturating ﬁlter paper with
whey ﬁltrate (pH 4.5–4.7) containing high concentration of phage.
Phage titre was not reported however, phages were found to remain
viable for up to 78 months stored at ambient temperature. Further work
is needed to look at stabilising phage in porous substrates.
4.5. Key points regarding drying of bacteriophage formulations
Phage drying and encapsulation can be performed using spray
drying, freeze drying and spray freeze drying techniques. Freeze drying
appears to be more successful that spray drying at maintaining high
titre values, although the ability of spray drying (or spray freeze drying)
provides very small particles thereby allowing them to be used in DPI
for pulmonary delivery, without the need for further milling. The best
conditions for the spray drying of phage have tended to be with low
outlet air temperatures (40–60 °C) which are much lower than typically
used in the spray drying of biological materials (70–100 °C). Some of
the viability loss in spray drying may be due to the atomisation process.
Survival rates during subsequent storage additionally depend on tem-
perature and humidity during storage and are important considerations
for the long term storage of phage. A review of published work on
drying of phage clearly indicates that phage survival varies from phage
to phage and is highly dependent on drying conditions and formulation
parameters, which need to be optimised for each phage (although for-
mulations involving disaccharides tend to be most successful). This
presents a considerable challenge for phage therapy since cocktails of
phage are typically needed. These need to be formulated for storage and
the active titre of individual phage may be highly variable if all phage
are formulated together.
4.6. Methods used for bacteriophage encapsulation in micro- and
nanoparticles
Bacteriophages may be encapsulated in protective micro- and na-
noparticles to overcome adverse storage and physiological conditions
en route to delivering the phage load at the site of infection (e.g. lungs,
intestinal delivery). Controlled release and sustained release strategies
for phage delivery applications may be achieved using a diverse array
of strategies. These include systems based on diﬀusion controlled re-
lease (e.g. solvent diﬀusion based osmotic pumps), matrix dissolution
and erosion-controlled systems, ion exchange swelling based systems.
Phage compatible formulation and encapsulation processes need to be
carefully designed to prevent damage to viral capsid and DNA/RNA
components and stabilisation of the structure of viral capsid and tail
proteins to prevent loss of phage viability during manufacturing op-
erations. It is important that the carrier encapsulating the phage is able
to withstand adverse environmental conditions for the duration of ex-
posure and is capable of delivering the bacteriophage to the site of
infection upon arrival [140,141].
A number of phage encapsulation studies using synthetic and nat-
ural polymers have utilised the emulsiﬁcation route followed by solvent
removal (Table 3). The dispersed phase usually comprises of the core
material and solvent carrying the active agent (bacteriophage) and the
polymer and a second phase which allows for the breakup of the inner
phase into droplets. The emulsion may be water-in-oil (W/O) more
typical for phage encapsulation [100], but could also be oil-in-water
(O/W) [142] and in some cases a third phase may also be present. Once
the droplets have formed, the solvent carrying the core material may be
removed, which leaves behind solid particles containing the active
agent in the core. Diﬀerent mechanical emulsiﬁcation techniques may
be used to break-up the inner phase into droplets, such as high-pressure
homogenisation, rotor-stator homogenisation, and ultrasonication.
When two immiscible liquids are put together, shearing force breaks up
the inner phase into small droplets. The droplet size uniformity how-
ever, is low as the shear applied does not remain uniform throughout
the container resulting in droplet heterogeneity with some droplets
being larger and some smaller. More advanced methods to produce
uniform droplets based on microﬂuidic and membrane based techni-
ques have thus far not been used for phage encapsulation (these
methods are discussed at the end of the paper).
Alternatively, phage containing polymer droplets have been pro-
duced via the extrusion technique [143]. The droplet may form in the
air or into another liquid. The dispersed phase containing the polymer
and phage is extruded through a needle with a speciﬁc nozzle diameter
determining the size of the droplet [144]. Atomisation nozzles have also
been used to generate smaller droplets [78]. If the polymer requires a
gelling or crosslinking agent then the droplet may be collected in a bath
of the gelling agent [143,145,146]. Examples of this method are pre-
sented by the work of Ma et al. [143,145] and Dini et al. [122] where
the extrusion technique was employed to extrude alginate containing
phage droplets into a bath of calcium chloride which caused ionotropic
gelation. The process of gelation can occur in a number of ways de-
pending on the properties of the polymer/hydrogel. Other gelling
triggers apart from ionotropic gelation include, heating, cooling and
covalent crosslinking. Other techniques that have been used for phage
encapsulation in synthetic and natural polymers include polymer pre-
cipitation [147], photopolymerisation [148] and thermal phase inver-
sion [142,149].
Most papers on phage encapsulation in liposomes have used the
thin-ﬁlm hydration method [31,39,77,95,150]. Phage have been en-
capsulated in nanoﬁbers using electrospinning techniques
[101,106,118,151–153], in ﬁlms e.g. for wound healing and food bio-
control of pathogens [154,155] and in thin ﬁlm structures [148].
4.7. Polymers used for bacteriophage encapsulation
Studies on phage encapsulation have used a variety of hydrophilic
and hydrophobic polymers including agarose [148], alginate
[78,122,143–145,149,155,157,158], chitosan [143,156,158], pectin
[122], whey protein [149,154,157,159], gelled milk protein [149],
hyaluronic acid methacrylate [148], hydroxypropyl methyl cellulose
(HPMC) [57,123], poly(N-isopropylacrylamide) [147], Poly(DL-lacti-
de:glycolide) [100], polyesteramide [121,160], polyvinyl pyrrolidone
[101,118], polyethylene oxide/polyvinyl alcohol [106,151–153], cel-
lulose diacetate [153], polymethyl methacrylate [75,161]. Phages have
been encapsulated in diﬀerent morphologies including nanospheres,
microspheres, nanoﬁbers, microﬁbers, membranes and thin ﬁlm struc-
tures (Table 3). Triggers for phage release include polymer solvation,
polymer dissolution and erosion [153], polymer hydrolysis [100,162],
phase inversion induced by temperature [147], and pH triggered dis-
solution of polymer and enzyme driven polymer degradation [148].
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4.8. Encapsulation of bacteriophage in polymeric microparticles
Polymer phage encapsulation literature has focused largely on
gastrointestinal infections (Table 3). The drivers for encapsulation are
the need to protect phage from the harsh stomach environment ren-
dering free phage inactive or at any rate resulting in reduction in phage
titre. High doses of bacteriophage need to be delivered in a controlled
manner at the site of infection in order to eﬀectively reduce the con-
centration of infectious bacteria present there. This poses a consider-
able formulation and delivery challenge. Animal studies focusing on
gastrointestinal infections (discussed above) have shown poor eﬃcacy
outcomes due to the challenges associated with in vivo phage therapy.
Oral administration of bacteriophage for human or animal use requires
careful consideration of a number of factors including: the acidic pH of
the stomach, digestive enzymes (pepsin, proteases, lipases, amylase and
trypsinogen), bile salts, pancreatic juices, residence time in diﬀerent
intestinal compartments (duodenum, jejunum, ileum) and phage per-
meability into the mucosal lining where the infection may reside.
Without proper formulation, phage may easily be inactivated due to
exposure to adverse environmental conditions. Carriers designed to
protect the active agents e.g. from the harsh gastrointestinal environ-
ment may also be used to trigger their release. An important example of
this is pH dependent release of encapsulated phage [75], exploiting the
variation in pH throughout the GI tract; carriers may be designed to
respond to speciﬁc pH which diﬀers from the stomach (pH 1–3) to the
small intestine (pH 5.5–6.5) and the colon (pH 6.5–7.2) [141]. Gastric
emptying rates are another important factor and need to be considered
in the design of phage encapsulation systems for oral use. Previous
studies indicate that in humans gastric emptying of small microcapsules
(< 2 mm) is rapid (~0.5–1.5 h) and is not greatly aﬀected by the di-
gestive state of the individual [163]. Gastric emptying times and en-
vironmental conditions in other animals may be quite diﬀerent to those
in humans e.g. gastric emptying times in pigs is longer (~1.4–2.2 h)
[164]. A suitable biocompatible carrier encapsulating the phage may be
required to protect and circumvent natural processes of the biological
system e.g. the acidity of the stomach environment [75]. Triggered
release of the phage at the site of infection needs to be engineered into
the delivery system. For example, the gastrointestinal tract may be
modelled as a distinct set of compartments (duodenum, jejunum, ileum
etc.) with each compartment having diﬀerent environmental conditions
(with diﬀerent pH and transit times) [165]. Release of phage in the
infected colon may be the desired outcome. High capsule erosion rates
triggered by a high pH early in the gastrointestinal tract may result in
phage release too early with poor phage therapy outcomes. The harsh
environment of the digestive system renders many sensitive therapeutic
agents e.g. proteins and phage inactive when administered without due
consideration to proper formulation [122,166–168]. Owing to the
nature of the infection, ﬂuctuations in physiological conditions may
also need to be considered and may indeed be put to use to trigger
release at the site of infection [141]. Consideration of particular in-
fection speciﬁc symptoms that might inﬂuence the delivery of the
phage needs to be taken into account. For example, the onset of
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hydroxypropyl 
methylcellulose
(HPMC); hyaluronic 
acid methacrylate 
(HYMA); Poly(DL-
lactide:glycolide)
(PLGA); Polyvinyl 
alcohol (PVA);
Polyvinyl 
pyrrolidone (PVP); 
cellulose diacetate
(CDA); polyethylene 
oxide (PEO); whey 
protein (WP)
water-in-oil emulsion
(W/O); water-in-oil-in-
water double emulsion
(W/O/W); extrusion (E);
gelation (G);
electrospinning (ES); wet 
spinning (WS); solvent 
evaporation (SW); 
precipitation 
polymerisation (PP); liquid 
phage filled capsules
(LPFC)
polysaccharides
(PS);
sucrose (Suc);
other sugars (S);
chloroform as 
solvent (Chl); 
others (O);
aqueous 
solvent (Aq)
food 
contamination 
(FC); 
nasal carriage 
of infectious 
organism 
(NC); 
gastrointestinal 
/ respiratory / 
wound 
infections 
(G / R / W);
simulated 
gastric fluid 
(SGF); 
intestinal 
fluid (SIF); 
phosphate 
buffer saline
(PBS);
sphere
fibre
film
acid exposure (AE); cascade 
impaction study (CI); storage 
studies (SS); nasal inserts (NI);
clinical case studies (CCS); 
thermally responsive polymer
(TR); edible coating (EC); 
exposure to degrading enzymes
(EEnz ); exposure to bile salts
(BS); animal studies (AS);
exposure to bile salts (BS); 
+/- indicates phage protection / 
damage
[100] Pa Sa PLGA; PVA W/O/W – SE - R Buffer ~ 10 µm CI; SS
[123] Sa HPMC Freeze drying S + O NC Sterile N/A NI; SS;
[155] Ec L Alginate E + G - FC N/A N/A SS;
[160] Ec P S Polyamide Casting Suc W PBS N/A SS;
[121] P Pa S Polyamide Casting Suc + O W N/A ~ 100 µm CCS
[147] Se Polyamide PP - W Water ~500 nm TR
[154] Ec WP Imbibition O FC SGF/SIF ~100 µm EC; SS;
[158] Ec Chitosan + alginate E + G - G SGF/SIF N/A AE(+); EEnz (+); BS (+)
[149] Ll Skim milk + rennet W/O + G - G SGF/SIF ~ 100 µm AE(+); EEnz (+);
[149] Ll Alginate E + G - G SGF/SIF ~ mm AE(-); EEnz(-);
[149] Ll Alginate + WP E + G - G SGF/SIF ~ mm AE(+); EEnz(+);
[159] Sa Alginate + WP E + G Suc; S; PS; O G - < 1 mm AE (+); SS;
[145] Sa Alginate E + G CaCO3 G SGF/SIF < 1mm AE(+); EEnz(+); BS (+);
[122] Ec Alginate; Pectin E + G - G SGF/SIF ~ mm AE (+); EEnz (+)
[143] Se Chitosan + alginate E + G - G SGF/SIF < 1mm AE(+); EEnz (+); BS (+); SS;
[78] Se Alginate E + G CaCO3 G SGF/SIF ~100 µm AE (+); EEnz (+); BS (+); SS; AS
[59] Se Alginate E + G Other G - - AS;
[75] Ec Eudragit S100 Spray drying - G SGF - AS; SS;
[57] Ec HPMC LPFC - G - - AS
[157] Se Alginate + WP E + G PS G SGF/SIF < 1 µm AE (+); EEnz (+); BS (+); SS;
[101] Ec PVP ES / WS Aq - Buffer Ø~100nm/ ~10µm 
[152] Ec PVA ES Aq - Broth Ø ~500 nm SS;
[151] Ec PVA ES Aq - Broth Ø ~500 nm SS;
[118] Ec PVP ES Trehalose; O - Buffer Ø ~100 nm SS;
[106] Ec Alginate + PEO W/O + E + G + ES Chl FC Buffer Ø ~ µm SS
[106] Ec PEO ES (coaxial) Chl FC Buffer Ø ~ 1 µm Core-shell; SS
[153] Ec PEO; CDA ES (coaxial) Chl FC Buffer Ø ~ 1 µm Core-shell
[148] Sa HYMA photo-crosslinking - - Buffer - Enzyme triggered release
[142] Sa Soya bean oil O/W surfactant W - - Nano-emulsions
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diarrhoea in humans causes the osmotic gradient between the epithelia
and colon to decrease resulting in increased ﬂuid leakage and shorter
transit times [169]. Changes in pH have been observed in the intestine
during infection which can directly aﬀect the microbial population as
well as transit times in the GI-tract [170].
Pathogens that cause systemic diseases may spread by the faecal/
oral route and may cross the intestinal epithelial barrier by transloca-
tion. The small intestine and the ileum are scattered with lymphoid
tissue that forms the Peyer's patch (PP) nodules. The PP nodules are
overlaid by the follicle-associated epithelium (FEM) displaying
Microfold cells (M cells). A large number of pathogens infecting the
human body take advantage of this route to gain access to the host
tissues. Salmonella typhimurium [171], E. coli [172] and many other
pathogens have been shown to adhere preferentially to M cells. Tar-
geting the M cells in the PPs may oﬀer the opportunity to deliver phage
accurately at the site of infection. Using anti-M-cell monoclonal anti-
bodies as speciﬁc ligands, adsorption of phage containing micro- or
nanoparticles (e.g. liposomes) into PPs may be used to target the M-cell
membrane [173].
The micro/nanoparticles must possess speciﬁc physicochemical
properties such as size, zeta potential and hydrophilicity/hydro-
phobicity balance contained within a narrow range of values [174].
Enhancing phage residence time inside the intestine may
exploit the mucoadhesive property of certain molecules e.g. alginates
[78,175,176]. This approach has not met with universal acceptance
since the superﬁcial mucus layer in the intestine is cleared at a rate
between 50 and 270 min, potentially removing anything bound to it.
Nanocarriers coated with polyPEG, hyaluronic acid or decorated with
vitamin B12 have been shown to have a greater ability to diﬀuse
through the mucus layer [177] thereby avoiding mucoadhesion.
There is scope for the development of innovative strategies to de-
liver phage encapsulated in micro- and nanoparticles for diﬀerent
target clinical applications. Chemically modiﬁed biopolymers provide
many opportunities for phage encapsulation including aliphatic polye-
sters, polyamides, polycarbonate and poly(amino acids). Synthetic
polymers, like Eudragit® are a family of pH responsive poly-
methacrylate polymers; Eudragit® L100 dissolves at pH 6 and Eudragit®
S100 at pH 7. These polymers are commercially available (Evonik,
Darmstadt, Rohm Pharma Germany) and are widely used in the pre-
paration of microspheres or for their coating. Eudragit® has been suc-
cessfully used for the production of microspheres encapsulating drugs
for colon delivery [178–182]. Combining Eudragit® with other biode-
gradable polymers (mentioned above) may allow tailored systems for
phage intestinal delivery. “Smart” stimuli responsive polymers with
modiﬁable properties have been studied for various applications with
tunable pharmacokinetics [147,148,183].
Particle size, surface charge and presence of ligands on the carrier
surface play an important role in delivery and have so far not been
extensively exploited for targeted phage delivery. A vast choice of
natural and synthetic polymers is available oﬀering considerable op-
portunities to tailor the encapsulation and subsequent release char-
acteristics of phage for diﬀerent biomedical applications. Many carrier
systems have been explored for controlled release of therapeutic agents;
these include polysaccharide polymers, synthetic polymers, liposomes,
and micelles, thereby permitting use of a multitude of diﬀerent strate-
gies for encapsulation and release based on diﬀerent stimuli.
Polymer based controlled release systems have been engineered for
the delivery of therapeutic agents for enteric applications including
treatment of ulcerative colitis, Crohn's disease [184], colorectal cancer
and food poisoning as well as many others [185]. The concentration of
bacterial species in the upper GI tract is approximately 103–104 CFU/
ml, largely composed of Gram positive facultative anaerobic bacteria.
In the colon however, this increases signiﬁcantly to 1011–1012 CFU/ml
[186] and is largely composed of anaerobes such as Bacteroides,
Biﬁdobacteria, Eubacteria, Clostridia, Enterococci and Enterobacteria. To
survive in this environment bacteria utilise undigested substrates pre-
sent in the small intestine. Carbohydrates like di- and tri-saccharides
and polysaccharides are fermented by these organisms [187]. En-
capsulation using natural polysaccharides is attractive due to their
biodegradability by human enzymes. Microbes produce enzymes such
as β-glucuronidase, α-arabinosidase, β-xylosidase, β-galactosidase, ni-
troreductase or urea dehydroxylase [188]. These enzymes metabolise
polysaccharides which the body is unable to process. Naturally occur-
ring polysaccharides are popular because they are low-cost and readily
available oﬀering a wide variety of structures and properties [189,190].
Other polysaccharides used for drug delivery applications include;
cellulose derived biopolymers e.g. hydroxypropyl methylcellulose,
pectin derived biopolymers e.g. polygalacturonic acid, guar gum, car-
rageenans, carob bean gum (galactomannans) and dextrin. Amylose, a
derivative of starch has been used to develop commercially available
drug delivery systems, COLAL® and COLAL-PRED® for colonic diseases.
These polysaccharides utilise the role of enzymatic action by microﬂora
to release the encapsulated agent [191,192].
Alginate and chitosan have been used in a number of studies to
encapsulate bacteriophage (Table 3). Sodium alginate is an anionic
linear polysaccharide composed of alternating blocks of β-(1→ 4)-
linked D-mannuronic acid (M) and α-(1→ 4)-linked L-guluronic (G)
residues. The encapsulation of phage in alginates is achieved using mild
processing conditions; alginate gelation is achieved by crosslinking of
carboxylate anions of guluronic acid and calcium ions. Chitosan is a
cationic hydrophilic polysaccharide obtained by partial deacetylation
of chitin; it has been studied for its muco-penetrative and tight-junction
penetration properties [193,194]. Penetration of the mucosal anionic
surface by chitosan is determined by the amino groups [195]. Lameiro
et al. [196] showed encapsulation of an adenoviral vector; for mucosal
delivery of vaccines; encapsulation eﬃciency over 84% was achieved
with a chitosan coating. Premature release in aqueous media as a
consequence of the swelling characteristic of chitosan was observed.
Takeuchi et al. [197] showed that chitosan coated sub-micron lipo-
somes interacted with the gut mucosa and had longer residence times in
the GI tract. Pectin has been used for the encapsulation of phage [122].
Pectin is a polysaccharide of partial methyl ester of α-D-galacturonic
acid (poly-Gal) interrupted with (1→ 2)-α-L-rhamnose units. Pectin
forms rigid gels through crosslinking of galacturonic acid with multi-
valent cations. Pectin incorporated in liposome nanocomplexes has
been shown to result in increased intestinal mucoadhesion and pro-
longed retention in the intestinal mucosa [198].
4.8.1. Protection of bacteriophage from stomach acid, pepsin and bile salts
Alginate and chitosan have been widely used to encapsulate a
variety of bacteriophage for oral delivery applications (Table 3). The
porosity of alginate gel micro-beads aﬀects phage susceptibility to acid
damage (when encapsulated phages have been exposed to SGF) due to
diﬀusion of acid into the microparticles [122,143,145]; hydrogel pores
tend be in the 5–200 nm range depending on the degree of crosslinking
[175]. Dini et al. [122] showed that acid exposure of E. coli phage
(pH 1.6, 30 min exposure) encapsulated in pure alginate microparticles
resulted in complete loss of viable phage. L. lactis phages encapsulated
in alginate were rapidly inactivated upon exposure to SGF at pH 2
[149]. A number of studies have shown that incorporation of calcium
carbonate (antacid) within alginate micro-beads helps protect en-
capsulated phage from acid damage [78,145]. The antacid containing
encapsulated phage were signiﬁcantly more stable exposed to SGF
acidic conditions in comparison with free phage.
Blending alginates with other polymers such as neutral gums (e.g.
Guar gum [122]), pectin [122], chitosan [122,143,145,158], whey
protein [149,157,159] and Eudragit [178] has been used to improve
the acid stability of alginate microparticles.
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A number of studies have indicated that phage encapsulated in al-
ginate-chitosan microparticles improves phage stability upon exposure
to acid conditions however, the protection was not complete
[122,143,145]. Ma et al. [143,145] showed that Salmonella and S
aureus phages are sensitive to the acidic pH of stomach and therefore
required protection for enteric treatment; this was aﬀorded by en-
capsulating phage in composite microparticles containing chitosan and
alginate. Only a ~2.5 log decrease in Salmonella phage Felix O1 was
shown after 1 h exposure to simulated gastric ﬂuid (containing pepsin)
at pH 2.4 compared with release of phage at pH 6.8 [143]. Kim et al.
[158] reported promising results for E. coli (Myoviridae) phage en-
capsulated in chitosan-alginate beads exposed to SGF (containing
pepsin, 1 h exposure at pH 2 and pH 2.5). For free phage, complete loss
of viable phage was noted within 5 min of acid exposure at pH 2 and
after 60 min exposure at pH 2.5. Additives such as maltose (dis-
accharide) have been added to formulations to improve storage stability
of alginate encapsulated phage to prevent phage loss during air drying
of microparticles. Ma et al. [143] exposed Salmonella Felix O1 phage
encapsulated in chitosan-alginate micro-beads to simulated bile (ex-
posure for 1 h and 3 h). Free phage showed a 1 log (1 h exposure) and
2 log (3 h exposure) reduction in phage titre. Microencapsulation in
chitosan-alginate beads resulted in complete protection of phage to bile
salt inactivation. Dini et al. [122] showed that acid exposure of E. coli
phage (pH 1.6, 30 min exposure) encapsulated in pectin aﬀorded im-
proved resistance to acid exposure and protection from pepsin in-
activation.
The concentration of encapsulating agent was found to be an im-
portant factor in aﬀording phage protection from SGF. Increasing whey
protein concentration in alginate-whey protein microparticles resulted
in better acid protection by reducing permeation rates of acid and di-
gestive enzymes [159]. Whey protein amino groups may sequester
protons diﬀusing through the polymer matrix. Tang et al. [157] en-
capsulated Salmonella Felix O1 phage in alginate-whey protein micro-
particles (diﬀerent alginate: whey protein compositions) with high
phage loading 1010 PFU/g wet particles. Solutions with high polymer
concentrations (~> 5% w/v) were found to have high viscosity and
posed diﬃculties in extrusion and lead to a wider distribution of par-
ticle sizes [157]. Alginate-whey protein microspheres were found to be
better at protecting Salmonella Felix O1 phage in SGF compared with
alginate chitosan microspheres [143] prepared by the same group.
Exposure of encapsulated Felix O1 to bile acid (1 h and 3 h duration)
did not result in signiﬁcant change in phage titre [157].
4.8.2. Release kinetics of encapsulated bacteriophage
Most studies with alginate containing phage show slow release of
encapsulated phage over a 2 h–6 h period upon exposure to SIF
[143,158]. Most systems swell upon exposure to SIF and phage release
is due to diﬀusion and encapsulation matrix degradation. Ma et al.
[143] showed that S. aureus phage K encapsulated in chitosan-alginate
micro-beads showed a sustained release rate over a 6 h period (ex-
posure to SIF pH 6.8). Microspheres were seen to swell and disintegrate.
Addition of calcium carbonate in alginate-chitosan micro-beads slowed
down the release rate. This was attributed to excess Ca2+ ions slowing
the alginate hydrogel dissolution [145].
Kim et al. [158] exposed E. coli (Myoviridae) phage encapsulated in
chitosan-alginate beads to SIF (0.1% bile and 0.4% pancreatin, pH 7.5,
37 °C, 6 h exposure). Sustained release of E. coil phage encapsulated in
chitosan-alginate beads over a 6 h period was noted [158]. Sustained
release of phage (from beads) was shown to result in a ~3 log reduction
in the in vitro concentration of E. coli 157:H7 after 5 h (compared with
~4 log reduction by free phage). The starting concentration of bacteria
was 106 CFU/ml. After 10 h of incubation in SIF, both free phage and
encapsulated phage were unable to arrest bacterial growth (comparison
with untreated controls) possibly due to presence of phage resistant
mutant bacteria. Colom et al. [78] showed the in vitro release kinetics
in SIF (40 min exposure, pH 8, 1 mg/ml pancreatin, 10 mM bile salts,
42 °C) for three Salmonella phages (ϕ20 (podovirus), ϕ78 (podovirus)
and ϕ87 (myovirus)) individually encapsulated in alginate micro-
particles containing CaCO3. Almost complete phage release was re-
ported within 40 min of exposure to SIF.
Microparticles with diﬀerent compositions of alginate-whey protein
encapsulating Salmonella Felix O1 phage were exposed to SIF (pH 6.8)
for 6 h [157]. The microparticles were found to swell and eventually
disintegrate. Encapsulated Salmonella Felix O1 phage showed sustained
release proﬁles which varied depending on the amount of polymer
content of the particles. For the same alginate content, increasing the
whey protein concentration was found to slow the phage release rate.
Whey protein hydrogels tend to swell readily at pH values above the
protein isoelectric point (IEP ~pH 5.1) [199]. Pancreatin may also
degrade whey protein provided it is able to diﬀuse into the hydrogel
structure. This may explain increasing erosion rates after an initial
period of exposure to SIF. Both whey protein and alginate possess ne-
gatively charged functional groups which would result in electrostatic
repulsion and swelling of the gel upon exposure to alkaline SIF. Algi-
nate-whey protein encapsulated S. aureus phage K released phage over a
2 h period upon exposure to SIF (pH 6.8) [159]. The microspheres were
seen to swell and eventually disintegrate with sustained release of
phage. Changes in formulation resulted in modest diﬀerences in the
release proﬁles. Dried microspheres resulted in slower release of phage.
Increasing concentrations of either alginate or whey protein retarded
the release of phage K. L. lactis P008 phage encapsulated in alginate-
whey protein showed a sustained release rate upon exposure to SIF over
a 2 h period [149]. Pre-exposure to SGF followed by exposure to SIF
resulted in a ~1 log reduction in total phage released. Gelled milk
protein microspheres were also found to be suitably protective of P008
phage and showed sustained release of phage upon exposure to SIF over
a 2 h period.
4.8.3. Eﬀect of size of beads
Particle size was found to be an important factor inﬂuencing phage
protection from SGF for acid permeable beads [159]. Alginate-whey
protein microparticles having the same composition but diﬀerent mean
sizes showed larger particles protected phage better compared with
smaller microparticles [159]. Larger particles keeping phage further
away from the acid environment were better at protecting phage from
acid damage [157]. However, larger particles are expected to experi-
ence more mastication [159] in the mouth and longer gastric retention
[163]. Samtlebe et al. [149] encapsulated L. lactis P008 phage in en-
zymatically gelled milk protein microcapsules with a small mean par-
ticle size (~130 μm) which was shown to protect phage exposed to SGF
at pH 2 for up to 2 h. Colom et al. [78] showed that three Salmonella
phage individually encapsulated in alginate microparticles (si-
ze ~ 150 μm) containing CaCO3 were able to protect the phage from
exposure to SGF although reduction in phage titre was noted for phage
~3.1 log reduction ϕ78 and ~2.4 log reduction ϕ87. No loss of titre
was noted for phage ϕ20.
Future studies may want to focus on developing methods to control
and tailor the porosity of the microcapsule shell to protect encapsulated
phage from SGF acidity whilst controlling the phage release rate.
4.8.4. Storage stability
Wet alginate-whey protein microspheres containing encapsulated S.
aureus phage K showed no loss in phage viability over a six week sto-
rage period (stored at 4 °C) [159]. Dried microspheres (with added
maltose) were shown to retain phage viability over a two week storage
period (no reduction in phage titre when stored at 4 °C and 20% re-
duction in phage titre when stored at 23 °C). Colom et al. [78] stored
Salmonella phage encapsulated in alginate/CaCO3 microparticles at 4 °C
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for six months and showed only a slight (~25%) reduction in phage
titre. Tang et al. [157] air dried (at 22 °C) Salmonella Felix O1 phage
encapsulated in alginate-whey protein microparticles and found an 8-
log reduction in phage titre. Addition of maltodextrin to the alginate-
whey protein microspheres stabilised the phage resulting in a< 0.5 log
reduction in titre post-air drying (drying time 30 h, at 22 °C). No sig-
niﬁcant loss in Salmonella Felix O1 phage titre was observed for air
dried particles over a 2 week storage period (stored at 4 °C and 23 °C).
Phage encapsulated in wet alginate-whey protein microspheres stored
at 4 °C for 6 weeks showed no signiﬁcant loss in phage titre.
4.8.5. Bacteriophage encapsulation in synthetic polymers
Surprisingly few studies are available on phage encapsulation in
synthetic polymers. Puapermpoonsiri et al. [100] freeze dried lytic
Staphylococcus aureus and Pseudomonas aeruginosa phage encapsulated
in PLGA (poly(lactic-co-glycolic acid)) microspheres prepared using an
W/O/W double emulsion technique (using dimethylformamide, DMF as
organic solvent). The microsphere size was designed to deliver the
encapsulated phage via inhalation using a dry powder inhaler (1-5 μm).
The phage encapsulated microparticles had low bulk density and
aerodynamic diameter ~ 4 μm suitable for respiratory delivery. Phage
activation was retained post-particle formation and sustained phage
release kinetics was noted upon exposure of particles to PBS buﬀer over
a 6 h period. Phage release showed an initial burst release (within
30 min for microparticles suspended in buﬀer) followed by a longer
release over ~6 h suggesting either inhomogeneous distribution of
phage within the microparticles or reﬂecting the dissolution kinetics of
the polymer microparticles [100]. The formation of phage loaded PLGA
microspheres necessitated a solvent evaporation step (accomplished
using freeze drying). No viable phage were recovered from the particles
after 7 days of storage at either 4 °C or 20 °C. Phage inactivation due to
exposure to organic solvent (dichloromethane) posed a problem. Mat-
subara et al. [200] evaluated the kinetics of the loss of viability of a
ﬁlamentous phage exposed to four water miscible organic solvents
ethanol, acetonitrile, dimethylsulfoxide and DMF; these solvents dis-
rupt protein conformation and enzymatic activity [201].
Stanford et al. [75] used Eudragit ES100 (methyl methacrylate-co-
methacrylic acid polymer) for Escherichia coli speciﬁc phage encapsula-
tion for cattle treatment. They showed high sensitivity of the phage to the
acid in the gastric environment. However, encapsulated phage showed
improved viability and in vivo reduction in faecal shedding of E. coli
following induced infection (discussed earlier in the review). The poten-
tial of ES100 for encapsulation of phage is also reported in a patent [202].
A number of other published studies have looked at phage encapsulation
in polyester amide ﬁlms for wound healing applications [121,160]. Thin
biodegradable polymer ﬁlms impregnated with a mixture of lytic bac-
teriophage (containing a mixture of lytic phage (trade name, Pyophage)
against P. aeruginosa, E. coli, S. aureus, Streptococcus, and Proteus mirabilis,
sold under the trade name PhagoBioDerm) was employed Markoishvili
et al. [121] to treat skin infections.
Hathaway et al. [147] encapsulated S. aureus phage K in poly(N-
isopropylacrylamide), a thermally responsive polymer. Phage were
encapsulated in PNIPAM nanospheres (~500 nm) which undergo a
fully reversible temperature dependent phase transition at a lower
critical solution temperature (LCST) which results in a change in the
particle size due to polymer shrinkage and expulsion of water from the
nanospheres along with the phage contained therein. The LCST for
PNIPAM can vary between 32 °C to 36 °C depending on polymer
properties [147]. The PNIPAM encapsulated phage nanoparticles were
grafted on to non-woven polypropylene ﬁlms (mimicking a wound
dressing ﬁlm) [147]. Evidence of temperature dependent phage release
data was somewhat limited in this paper.
Bean et al. [148] encapsulated S. aureus phage K in an agarose slab
covered in a thin ﬁlm of a photo-cross-linkable hyaluronic acid me-
thacrylate (HAMA) polymer. The HAMA polymer was shown to degrade
in the presence of hyaluronidase enzyme secreted by S. aureus (a rare
example of using a virulence factor secreted by the pathogen as a
trigger for phage release).
Milo et al. [203] describe the use of a pH responsive coating for
urinary catheters which may immobilise phage and release these upon
onset of infection by Proteus mirabilis. Urinary tract infections may re-
sult in an increase in pH due to bacterial urease which could be used as
a trigger to dissolve an upper layer of pH responsive polymer (e.g.
methyl methacrylate-co-methacrylic acid; Eudragit S100) as part of the
construction of the catheter hydrogel coating.
4.9. Bacteriophage encapsulation in liposomes
Relatively few published studies have looked at encapsulation of
bacteriophage in liposomes (see Table 4). In nearly all cases the thin-
ﬁlm hydration method has been used for liposome preparation. Brieﬂy,
this entails dissolving lipids in an organic solvent (typically chloroform)
followed by solvent evaporation under vacuum leaving a dry lipid ﬁlm.
Addition of an aqueous phage suspension to the dry lipid ﬁlm results in
the stacks of liquid crystalline lipid bilayers becoming ﬂuid and swel-
ling. Agitation of the solution results in detachment and closure of the
lipid layers thereby forming relatively large and heterogeneous multi-
lamellar liposomes. Extrusion of the liposome mixture through porous
membranes has been be used to form smaller liposomes [77,150]. Nieth
et al. [47] employed a novel method proposed by Weinberger et al.
[204] to prepare phage encapsulated in giant unilamellar vesicles
(GUV) using gel-assisted formation of GUV by rehydrating lipid layers
on polyvinyl alcohol gels. This technique aﬀorded a number of ad-
vantages over the traditional thin ﬁlm hydration method. Firstly, faster
hydration kinetics due to aqueous solvent penetration through lipid
ﬁlm stack was achieved due to the diﬀerence in chemical potentials
between the dry PVA supporting the lipid stacks and the liquid phase
above [47]. Secondly, better encapsulation phage eﬃciency was
achieved with the phage incorporated within the cast PVA gel ﬁlms
instead of the rehydration buﬀer. Confocal microscopy showed visual
evidence that this method allowed good encapsulation of a ﬂuores-
cently labelled E. coli λ phage. When the E. coli λ phage was provided
externally with the swelling buﬀer, no encapsulation was observed
suggesting that the lipid stacks themselves were impermeable to the
phage present in the external solution. The GUV prepared using this
technique resulted in large vesicles (5 μm–50 μm). Extrusion of GUV
through a 5 μm pore size membrane resulted in reduction in vesicle size
to< 5 μm however, E. coli λ phage concentration was below the sen-
sitivity of the ﬂuorescence microscope. No quantitative phage titres
were carried out by breaking the liposomes and releasing their phage
cargo. Nieth et al. [47] also employed the inverse emulsion liposome
preparation method of Pautot et al. [205] to encapsulate the ﬂuorescent
E. coli λ phage. GUV prepared using the inverse emulsion method had
an average diameter between (10 μm–15 μm). Nieth et al. [47] also
showed signiﬁcantly greater intracellular uptake of liposome en-
capsulated ﬂuorescent E. coli λ phage (compared with free phage) in a
macrophage-like human monocytic cell line.
Colom et al. [77] encapsulated S. enterica phage in cationic lipo-
somes (liposome size range ~ 200–800 nm). They suggested that ca-
tionic liposome loaded bacteriophage would achieve two objectives: (i)
to protect the bacteriophage from gastric acids and (ii) act as a pro-
moter for mucoadhesiveness owing to their positively charged surfaces
thereby prolonging intestinal residence time of phage [77]. The Sal-
monella phages were encapsulated in unilamellar liposomes using the
thin ﬁlm hydration method. In vitro studies showed that encapsulated
phage were released upon exposure to SIF within 60 min. Exposure to
SGF resulted in loss of phage viability with modest protection of S.
enterica phages aﬀorded by encapsulation in cationic liposomes com-
pared with free phages. The intestinal residence time of liposome en-
capsulated phages in the cecum of newly hatched chickens was
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considerably longer compared with free phage (refer to earlier section
on animal studies). This was attributed to the small size and mu-
coadhesive properties of the cationic liposomes. Nieth et al. [47] also
encountered problems in terms of bacteriophage encapsulation in li-
posomes. Encapsulation eﬃciency, control over the size, phage titre,
were found to be key issues that need addressing in future studies.
Balcao et al. [206] encapsulated lytic bacteriophage (against Salmonella
and E. coli) by emulsifying an aqueous phage solution (water phase) in a
lipid melt (oil phase) using homogenisation technique resulting in na-
noparticles in the size range (85–200 nm). The size of the nanoparticles
showed stability over a 3 month storage period at room temperature.
Quantitative results on the antibacterial activity of encapsulated phage
were not provided although lytic activity of encapsulated phage was
observed following phage release.
Singla et al. [39] evaluated the encapsulation of K. pneumonia phage
(belonging to the Podoviridae family) in liposomes prepared using dif-
ferent phospholipid: cholesterol ratios with additional charge inducing
agents to prevent liposome aggregation. The liposomes were prepared
using the ﬁlm-hydration method and ranged in size between 500 and
1000 nm. Phage encapsulation eﬃciency was shown to be higher for
the electrostatically stabilised positively charged liposomes (containing
stearylamine) with higher lipid content. Phage encapsulated liposomes
stored at 4 °C for 9 weeks were stable both in terms of size as well as
phage titre. Storage at ambient temperature or 37 °C resulted in
changes in size (increase) as well as loss of phage titre. In vivo toxicity
testing and biodistribution of phage was carried out in mice. Brieﬂy,
~108 PFU dose was delivered to mice via the intraperitoneal route.
Rectal temperatures were taken hourly (for the ﬁrst 5 h) and daily (for
4 days post-phage treatment). No adverse change in temperature or
symptoms of lethargy or sickness was noted for the liposome/phage
treated animals. Phage distribution in lungs, liver, spleen and kidney
were quantiﬁed. Blood titres of phage reached ~10 PFU/ml shortly
after injection (within 1st hour) for both free phage and liposome en-
capsulated phage. Liposome encapsulated phage remained in blood and
other organs for longer periods compared with free phage treated mice.
Free phage were cleared from the blood and organs 48 h post-treatment
whereas liposome encapsulated phage were detectable in blood and all
organs up until day 3 (albeit at low concentrations ~ 1 PFU/ml) post-
treatment and remained detectable in the spleen up until day 14.
Liposomes are spherical structures delimited by a double layer of
bulky amphiphilic lipids which encloses an aqueous phase. Charge, size,
ﬂuidity of the bilayer, lamellarity and surface functionalization are the
major parameters that regulate liposomes fate in vivo and in vitro. Size
and lamellarity vary as a result of the manufacturing process. Fluidity
and superﬁcial charge depend on the chemical nature of the lipids and
their relative ratio. Liposomes are also highly biocompatible and they
have been widely used in the last ﬁfty years to encapsulate hydrophilic
or hydrophobic therapeutic agents in their aqueous core or within the
bilayer thereby enhancing drug bioavailability and stability over time.
Encapsulated liposomes are a promising drug delivery system and
pharmaceutical carrier of choice for numerous applications [207].
From a clinical viewpoint the potential ability of liposome en-
capsulated phage to enter live cells containing intracellular pathogens
is of crucial importance e.g. M. tuberculosis or other intracellular bac-
teria e.g. S. aureus or E. coil. The surface of liposomes may be functio-
nalized to achieve various goals: (i) attachment of speciﬁc ligands for
targeted delivery of liposome cargo; (ii) attachment of hydrophilic
polymers to increase systemic circulation time and slow release of
bacteriophage cargo; (iii) attachment of various labels to monitor the
fate of the bacteriophage loaded liposomes; (iv) incorporation of posi-
tively charged lipid derivatives or positively charged polymers e.g. to
aid mucosal adhesion thereby improving residence time in the gastro-
intestinal tract; (v) protection of bacteriophage from physical and
chemical stresses; (vi) liposome encapsulated bacteriophage may result
in modulated immune response to the presence of the bacteriophage in
the body. Ta
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4.9.1. Liposome size, charge and surface modiﬁcation e.g. PEGylation
Previous studies have found that by reducing the size of particles
below 1 μm (i.e. nm scale) enhancement in liposome nanoparticle ac-
cess to infection sites deep in intestinal mucosa may be achieved
thereby improving phage therapy eﬃcacy by targeting bacterial re-
fugees residing in these diﬃcult to access niches [197,198]. The re-
sidence time of nanoparticles has been shown to be longer compared to
larger microparticles; larger particles are more prone to peristaltic ac-
tion and rapid transit through the colon. Nanoparticles have been
shown to interact with epithelial cells and show increased retention
enabling selective delivery of therapeutic agents into the colitis tissue
[208]. Conventional formulations have so far not exploited this ability
causing deposition in regional areas. Smaller particle sizes are able to
take advantage of endocytosis for internalization into the epithelial
cells of the colon. They attach to specialised epithelial M cells (dis-
cussed above) which are responsible for antigen transport from the
lumen to the immune system. These M cells are also responsible for
uptake of nanoparticles by transcytosis [209]. Microparticles have been
shown to adhere to the inﬂamed mucosal wall whereas nanoparticles
are absorbed across the epithelial barrier [210].
Interactions between charged particles and the mucus may be an
appropriate strategy for intestinal delivery. Cationic delivery systems
adhere to the negatively charged intestinal mucosa thereby promoting
cellular uptake and subsequent drug release [211]. The mucins which
comprise the mucosa are also known to be negatively charged. Anionic
systems adhere to inﬂamed tissue via electrostatic interactions. The
presence of positively charged proteins in the inﬂamed regions typically
increases. Some authors suggest that unlike cationic particles which get
immobilised on the mucus, anionic particles are able to diﬀuse through
the mucus network due to decreased electrostatic interactions [170].
Other studies suggest that particles are entrapped within the mucin
mesh no matter what charge they carry since the mucus displays ne-
gatively and positively charged proteins. Hence, if a non-adherent ap-
proach is needed, the nanoparticle surface could be decorated with
speciﬁc moieties that confer so called ‘stealth’ properties [212]. In-
corporating poly(ethylene glycol) (PEG) on the surface of nanoparticles
has been shown to result in a hydrophilic surface chemistry that allows
unobstructed diﬀusion of nanoparticles through the epithelium. An
explanation for this is that surface modiﬁcation prevents strong inter-
action of nanoparticles with the mucus which typically prevents diﬀu-
sion to the colitis tissue [213].
Active targeting by surface functionalization of phage containing
nanoparticles e.g. liposomes with ligands for selective phage accumu-
lation at the site of infection may help increase the local concentration
of phage delivered thereby increasing their therapeutic eﬃcacy.
Monoclonal antibodies and peptides speciﬁc for target sites have been
used to increase speciﬁcity and enhance muco-penetrative properties
[214]. It is thought that by incorporating ligands targeting receptors
present at the site of infection may improve binding and thereby in-
tensify endocytosis. Possible receptors for targets in the inﬂamed colon
may include, ICAM-1 which is upregulated during inﬂammation,
mannose receptors and macrophage galactose-type lectin (MGL) (ex-
pressed by activated macrophages). The combined eﬀect of the small
particle size of nanoparticles, PEGylation and integration of mannose
ligands has recently been shown to increase penetration ability for
macrophage targeting [208].
Functionalization of liposomes for speciﬁc targeting may have an
attractive future for phage delivery applications. Some pathogenic mi-
croorganisms such as M. tuberculosis and S. enterica (serovar
Typhimurium) are able to survive speciﬁc antimicrobial machinery
causing persistent infections. Long-term residence is achieved by in-
ternalization in mononuclear phagocyte system (MPS). It is not fully
understood how these bacteria inhibit their clearance by the immune
system but common mechanisms include prevention of the normal
maturation of the phagosomal environment or blockage of the fusion of
the phagosome with endosome and lysosome. What happens afterwards
is even less clear; bacteria can remain stored for years in an asympto-
matic state that can suddenly be triggered into a potentially life-
threatening active state, especially for people with a weak or compro-
mised immune system. Liposomes innately accumulate in MPS due to
their interaction with serum proteins that accelerates phagocytosis. It
makes bacteriophage-encapsulated liposomes an appealing approach to
treat antimicrobial resistant bacterial infections that spread from within
the MPS. The rate of clearance depends on the physical/chemical
characteristics of the vesicle` surface. It has been shown that uptake by
MPS for liposomes is enhanced when phosphatidylserine incorporating
PEG is used. On the other hand, long-circulating liposomes with high
PEG value can accumulate at the site of infection due to increased
permeability. Agrawal et al. [215] have demonstrated that tuftsin, a
tetra-peptide, used as a homing-device improves liposomes uptake by
MPS cells but also stimulates these cells to take action against infec-
tions. Leishmaniasis, Aspergillus fumigatus and Mycobacterium tubercu-
losis infections have been treated with drug-loaded tuftsin-bearing li-
posomes and tuftsin-free liposomes and in all cases the treatment lead
to enhanced eﬀectiveness.
Phage therapy has recently been considered as an alternative to, or a
supplement for, antibiotic treatment for mycobacterial respiratory in-
fections. However, phage therapy for TB and other respiratory infec-
tions caused by non-tuberculosis mycobacteria (NTM) is complicated by
the intracellular nature of the infection. It is generally recognised that
phage do not diﬀuse across eukaryotic cell membranes and therefore
would be unable to infect the intracellular mycobacteria [48]. Using a
non-pathogenic mycobacterium, Mycobacterium smegmatis, infected
with a mycobacteriophage as a ‘Trojan horse’ to deliver phage to the
macrophage compartments in which M. avium resides, showed promise
when tested in vitro with infected macrophages [216]. However, when
used in a murine model of M. avium infection, this approach was less
eﬀective. It was deemed that the numbers of infected M. smegmatis cells
required, would deliver too large a dose of antigenic material to be
acceptable [217]. Alternative methods of delivery of phage to in-
tracellular mycobacteria have been sought. Looking to the relatively
routine use of liposome encapsulation for intracellular delivery of small
molecule drugs [218], Nieth et al. [150] recently suggested en-
capsulation of phage within liposomes may result in uptake of phage
and delivery to the required intramacrophage compartment to initiate
lytic infection of intracellular pathogens. To this end, they demon-
strated successful encapsulation of mycobacteriophage TM4 in giant
unilamellar vesicles. Furthermore, by encapsulation of a lambda phage
expressing yellow ﬂuorescent protein and ﬂuorescent labelling of
macrophage endosomal proteins, they were able to demonstrate in-
tracellular delivery and co-localisation of the lambda phage and the
endosomes; in Mtb infected macrophages, the mycobacterial phago-
some fuses with early endosomes. This demonstration that liposome-
encapsulated phage could gain access to the target mycobacteria sa-
tisﬁes a requirement for eﬀective therapeutic use of bacteriophage to
treat intracellular mycobacterial infections. A previous study using li-
posome encapsulation of frontline antituberculosis antibiotics, ri-
fampicin and isoniazid, showed enhanced treatment in a murine in-
fection model of Mtb compared with treatment with antibiotics alone
[219]. The eﬃcacy of a liposome-encapsulated mycobacteriophage to
treat Mtb infection in macrophages or animal models remains to be
demonstrated.
Encapsulation of bacteriophage in liposomes may be a potential
approach to tackle antibiotic resistant bacterial infections in wounds.
Previous studies have shown that topical applications of buﬂomedil
hydrochloride loaded liposomes in mice signiﬁcantly accelerate wound
epithelialization [220] in normal and ischemic tissue. Furthermore, by
modifying the liposome surface properties (e.g. charge), liposomes can
be trapped in gauzes [221] reducing the number of applications and
consequent costs. The surface of liposome vesicles can be modiﬁed with
hyaluronic acid (HA) in order to confer bioadhesive properties [222].
Indeed, HA-anchored liposomes were found to bind to the extracellular
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matrix (ECM) without compromising any of the liposome properties. A
marked enhancement of liposomal adhesion (in vitro) to a monolayer of
human epidermoid carcinoma cells was observed. Topical delivery of
bacteriophage-loaded liposomes would constitute a phage reservoir
localised in the area of the wound releasing phage at a high con-
centration over an extended period of time.
4.10. Bacteriophage encapsulated in electrospun ﬁbers
Fabrication of phage encapsulated polymer ﬁbers (diameters ran-
ging from tens of nanometers to microns) may readily be achieved using
electrospinning, by drawing a charged polymer-in-solvent solution onto
a grounded electrode whilst evaporating the solvent. A number of
studies have shown the feasibility of encapsulating phage in nanoﬁbers
using the electrospinning technique (Table 2). A number of diﬀerent
polymers have been evaluated for encapsulating phage in ﬁbers in-
cluding cellulose diacetate [153], polyethylene oxide [106,153], poly-
vinyl alcohol [151,152] and polyvinyl pyrrolidone [101,118]. Good
phage encapsulation results have been reported using water soluble or
chloroform soluble polymers [106,118]. Rapid dehydration during
electrospinning was shown to damage phages. Use of buﬀer and in-
corporation of sugars e.g. trehalose was shown to improve protection of
phage [118]. Protection of phages in core-shell ﬁbers using co-axial
electrospinning technique was shown to be particularly promising
[106,153]. Using immiscible solvents for the core (phage contained in
an aqueous core) and shell (shell polymer dissolved in an organic water
immiscible solvent) was found to stabilise the polymer jet resulting in
the formation of a stable core-shell ﬁber structure [106,153]. In this
process, aqueous solvent evaporation from the core is very slow thereby
overcoming drastic changes in osmotic pressure in the phage containing
core. Encapsulation of phages in nanoparticles formulated in an emul-
sion followed by electrospinning of the emulsion was another approach
that was shown to result in improved phage protection during elec-
trospinning [106]. Increasing polymer molecular weight or blending
diﬀerent polymers (e.g. cellulose acetate/PEO) was shown to result in
changes in the phage release kinetics from electrospun ﬁbers [153]. The
main reported mechanism of phage release from encapsulated ﬁbers is
typically swelling of ﬁbers upon exposure to solvent followed by
polymer erosion accompanied by phage diﬀusion and release. En-
capsulating phage in hydrophilic water soluble polymers results in
rapid phage release due to polymer dissolution whereas use of hydro-
phobic polymers or blends may allow tailoring of phage release to en-
sure slower release over a prolonged period.
The polymer and solvent combination used for ﬁber production
were found to be important factors in the formation of nanoﬁbers and
retention of phage viability therein. Lee and Belcher [101] spun ﬁbers
(diameters 100–200 nm) containing E. coli M13 phage which retained
infectivity against bacterial host when re-suspended in buﬀer. The
phage containing ﬁbers were spun from an aqueous polyvinyl pyrroli-
done buﬀered solution containing phage; the ﬁbers were captured as a
non-woven ﬁbrous mat. Concentration of viable phage in the ﬁbers was
not reported. Salalha et al. [152] and Kuhn [151] encapsulated T4, T7,
and λ E. coli phage in electrospun nanoﬁbers (diameter 250–400 nm)
prepared from aqueous poly(vinyl alcohol) (PVA) solutions. Nanoﬁber
encapsulated phage were shown to retain viability and remained stable
for three months stored at −20 °C and −55 °C and nearly so at 4 °C.
Salalha et al. [152] suggested that this method was a facile way of
preserving phage. Immediately after electrospinning, a 2 log loss in
phage viability was reported (T4 ~ 1%, T7 ~ 2%, and λ~ 1%). The
losses in phage viability during electrospinning may be attributed to
drying stresses due to rapid evaporation of solvent and drastic changes
in osmotic pressure experienced by phage. Dai et al. [118] investigated
electrospinning (diameter 100-200 nm) of E. coli T7 phage in SM buﬀer
using PVP as polymer (15% w/v) and trehalose (5% w/v) as excipient
as a means to improve phage stability for long term storage. Inclusion of
SM buﬀer had a signiﬁcant positive eﬀect on phage viability post-
electrospinning. The phage titre of PVP/SM buﬀer samples (with and
without trehalose) fell by no more than ~1 log following electrospin-
ning. Electrospinning phage-PVP solutions in deionised water resulted
in a 4 log reduction in phage titre. Addition of trehalose to deionised
water resulted in some improvement with a 2 log reduction post-elec-
trospinning, showing that trehalose had a protective eﬀect. Dai et al.
[118] also compared phage stabilisation using electrospinning with
freeze drying. Phage encapsulated in electrospun ﬁbers (made from SM
buﬀer with trehalose) were found to have similar titre compared with
freeze dried powder samples. Storage of phage T7 in electrospun ﬁbers
for eight weeks (stored at 20 °C) resulted in a 3 log reduction in phage
titres for samples prepared from SM buﬀer with/without trehalose.
Korehei and Kadla [106] evaluated emulsion electrospinning (pre-
encapsulating phage in ~800 nm alginate nanoparticles followed by
lyophilization and then re-suspension in a polymer containing solvent
followed by electrospinning) and coaxial electrospinning (incorporating
the phage in a protective core in a core-shell ﬁber structure) processes
to encapsulate E. coli T4 phage in polyethylene oxide ﬁbers. The process
of encapsulating phage in alginate nanoparticles resulted in a 1 log drop
in phage titre. Freeze drying the phage encapsulated in nanospheres did
not result in a drop in phage titre. Electrospraying the alginate sus-
pension on its own (without polyethylene oxide) resulted in a large
drop in phage titre from 108 PFU/ml to 103 PFU/ml. Polyethylene oxide
(PEO) is soluble in both aqueous and organic solvents making it a
suitable polymer for electrospinning. Polyethylene oxide ﬁbers en-
capsulating alginate nanoparticles were found to result in ﬁbers with a
bead-on-string morphology (ﬁber diameter ~ 1 μm). Dissolution of ﬁ-
bers in SM buﬀer showed a phage titre of 106 PFU/ml (a 2 log reduc-
tion). Fibers with diameter ~ 2 μm were prepared using a core/shell
approach with the ﬁber shell made using PEO in chloroform and the
core containing T4 phage in SM buﬀer [106]. Good lytic activity was
retained post-electrospinning with a high phage titre obtained
(108 PFU/ml) with ﬁbers dissolved in SM buﬀer. Storage stability of T4
phage in the core-shell ﬁbers after freeze drying (freeze drying condi-
tions were not reported in the paper and no details were given on
whether any excipients were added) was investigated (stored at
−20 °C, 4 °C and 20 °C) over a period of 30 days. No signiﬁcant loss in
phage titre was observed for samples stored at−20 °C and 4 °C. Storage
at 20 °C resulted in a signiﬁcant loss (> 6 log reduction) in phage titre.
Upon exposure of PEO ﬁbers to SM buﬀer, ﬁbers were seen to swell
followed by disintegration (within 10 min) resulting in release of phage
for the alginate-emulsion based ﬁbers and the core-shell ﬁbers. Initial
rate of phage release was faster from the core-shell ﬁbers (the resulting
ﬁnal titre was also higher) compared with the alginate nanoparticle
encapsulated ﬁbers. Korehei and Kadla [153] varied the molecular
weight (MW) of PEO (100 kDa–600 kDa) and blended hydrophilic PEO
with the hydrophobic polymer cellulose diacetate (CDA). E. coli T4
phage encapsulated in ﬁbers produced using diﬀerent PEO/CDA
showed slow release of phage depending on the PEO MW and the ratio
of PEO/CDA. Higher PEO MW (results in increased polymer entangle-
ments) and greater proportion of hydrophobic CDA (slower rate of
polymer swelling and erosion) resulted in slower release of phage.
4.11. Immobilisation of bacteriophage on surfaces including thin ﬁlms
Microbial bioﬁlms on medical devices e.g. urinary and central ve-
nous catheters, stents, implants, invasive health monitoring devices, are
a signiﬁcant healthcare problem and are responsible for a vast majority
of medical device associated infections. Bioactive packaging materials
are also attractive in other areas including food packaging e.g. ready-to-
eat meat, ready cut fruits and poultry [155]. Antibioﬁlm formation
strategies include oriented immobilisation by covalent attachment of
bacteriophage to polymer surfaces [223] or immobilisation of bacter-
iophage in stimuli responsive materials where release is triggered in
response to an external stimulus [148]. Although phage immobilisation
on surfaces may readily be achieved through passive adsorption [224],
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the process is ineﬃcient with loss of phage activity due to poor or-
ientation of phage tails needed to recognise and infect target bacteria.
Chemical biotinylation of the phage capsid head has been used for or-
iented immobilisation (to retain phage lytic activity by leaving the tail
ﬁbers free in order to capture bacteria) of a Salmonella enteritidis phage
on streptavidin-labelled magnetic beads [225]. Tolba et al. [226] used
phage display technology to introduce aﬃnity tags on the capsid head
to immobilise E. coli phage on streptavidin coated magnetic and cel-
lulose beads. Pearson et al. [223] covalently attached lytic E. coli and S.
aureus phage through reaction of primary amine groups on the capsid
head with R-COOH surface groups (generated using microwave plasma
in the presence of maleic anhydride) on polyethylene and polytetra-
ﬂuoroethylene surfaces. Anany et al. [227] and Lone et al. [155] uti-
lised the electrostatic interaction between the anionic capsid head of E.
coli O157:H7 and Listeria monocytogenes phage cocktails and poly-
vinylamine treated cellulose membranes. Modiﬁcation of cellulose
membranes resulted in greater numbers of infective phage oriented
correctly. A recent patent focuses on controlled covalent attachment of
bioactive bacteriophage to a hydrogel coating material for regulating
bioﬁlm development with examples focusing on bioﬁlm reduction on
urinary catheters [228]. An earlier patent gave examples of phage im-
mobilisation on nylon sutures for wound healing applications [229].
Cooper et al. [230] used carbodiimide oriented covalent attachment of
a tailed P. aeruginosa bacteriophage to magnetised multiwalled carbon
nanotubes. Preliminary results showed antimicrobial eﬃcacy of bac-
teriophage-nanocomposite conjugates against P. aeruginosa. Handa
et al. [231] employed chemical vapour deposition to make a smooth
aminosilane monolayer on a glass substrate. Subsequently, monolayers
of covalently bound Salmonella speciﬁc phage were attached to the
aminosilane monolayer using well-established sulfo-NHS (N-hydro-
xysulfosuccinimide) and EDC (1-ethyl-3-[3-dimethylaminopropyl] car-
bodiimide hydrochloride) chemistry [231]. Techniques for attachment
of phage to gold substrates has been investigated to increase their di-
agnostic utility as part of quartz crystal microbalance (QCM), surface
plasmon resonance (SPR) transduction based diagnostic platforms
[232] or direct detection as part of virus electrodes [233]. Recently,
Richter et al. [234] applied an electrical potential to align E. coli phage
T4 and drive them to the electrode surface resulting in head down, tail-
up orientation resulting in increased sensitivity of phage for bacteria
and a low detection limit for E. coli of 103 CFU/ml. Tawil et al. [235]
reported on the synthesis of colloidal phage-gold nanoparticle com-
plexes for the detection of a single S. aureus bacterium in a mixture of S.
aureus and E. coli using Dark Field Microscopy. The potential of phage
for biosensing applications including low-cost medical diagnostics may
require their coupling with novel materials (thin ﬁlm constructs,
magnetic, metallic, polymer nanoparticles, quantum dots) [24].
5. Future trends in bacteriophage formulation and encapsulation
5.1. Phage encapsulation using novel stimuli responsive materials
There is signiﬁcant scope for future research on encapsulation of
phage in novel stimuli responsive polymers utilising diﬀerent triggers
for phage release including light, temperature, pH, enzymes. A wide
range of external stimuli may be used to trigger self-assembly of phage
containing micro- and nano-particle structures (e.g. in micelles, nano-
gels, capsules, vesicles, core-shell particles, hybrid particle-in-particle
structures, emulsions and foams) and may induce their reversible or
irreversible disintegration, aggregation, swelling. Micro- and nano-
particles with surface grafted ligands may be used for targeted delivery
of phage cargo released at the site of infection. Stimuli responsive
homo-polymer and mixed-polymer brushes grafted on to microparticles
may be used to trigger phage release in response to changes in en-
vironmental or interfacial conditions. Phage may be encapsulated in
diﬀerent architectures e.g. thin ﬁlm structures as multi-layered ﬁlms,
hybrid ﬁlms combining polymers and nano- or micro-particles.
5.2. Phage encapsulation using membrane emulsiﬁcation
Advanced techniques may be applied for phage encapsulation to
precisely control the size and architecture of phage containing micro-
and nano-particles. To-date methods used for phage encapsulation have
not utilised state-of-the art processing techniques that could be applied
for the encapsulation of phage to achieve controlled dosage forms in
uniform micro- and nanoparticles. Membrane emulsiﬁcation (ME) is
one such process that allows formation of uniform drops by injecting a
Fig. 3. Membrane emulsiﬁcation (ME) methods that can be
used for phage encapsulation: (a) Cross ﬂow ME; (b) premix
ME; (c) Shirasu Porous Glass (SPG) microkit; (d) Micropore
Dispersion Cell; (e) axially oscillating membrane tube.
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dispersed phase liquid through a microporous membrane into the
continuous phase (Fig. 3 a). Alternatively, a pre-emulsiﬁed mixture of
the dispersed and continuous phase may be repeatedly injected through
the membrane (Fig. 3 b). To encapsulate bacteriophage, the formed
drops, typically composed of a mixture of the wall forming materials,
solvent(s) and phage, could be solidiﬁed under mild agitation using
various solidiﬁcation reactions or processes, such as free-radical poly-
merisation, polycondensation, ionotropic/thermal gelation, cooling
crystallization, and molecular or particle self-assembly triggered by
solvent evaporation [236]. The advantages of ME over standard
emulsiﬁcation procedures using high-pressure valve homogenisers or
rotor-stator devices are in higher drop size uniformity and lower energy
inputs and applied shear, which can be useful to preserve phage in-
tegrity. It is well known that bacteriophages are sensitive to mechanical
shearing [104,128]. In direct ME, the shear rate on the membrane
surface is ~103–104 s−1 however, uniform drops may be obtained
without any shear by spontaneous droplet formation driven by Laplace
pressure gradients [237]. The shear rate in high-shear mixers and col-
loid mills is typically ~105 s−1 and can exceed 107 s−1 in micro-
ﬂuidizers. The most common membranes used in ME are Shirasu Porous
Glass (SPG) (Fig. 3 c) and microsieve metallic membranes [238]. Shear
on the membrane surface required for drop detachment can be gener-
ated in various ways including; (i) using a paddle stirrer placed above
the membrane surface (Fig. 3 d) [239]; (ii) rotating membrane [240]
and (iii) oscillating membrane [241]. In the oscillating ME system, the
tubular membrane can oscillate tangentially clockwise or counter-
clockwise [242] or radially upward and downward (Fig. 3 e) [241],
with frequencies ranging from 10 to 90 Hz.
5.3. Phage encapsulation using microﬂuidic emulsiﬁcation
Bacteriophage containing microcapsules could be fabricated using
microﬂuidic devices with unprecedented uniformity and control over
the size, shape and morphology [243,244]. The process involves crea-
tion of drops in a variety of geometries consisting of micrometre length
scale channels designed to bring two or more immiscible ﬂuid streams
into contact with one another. This is followed by conversion of the
generated drops into solid particles (using techniques discussed earlier).
The variation of drop sizes in microﬂuidic devices is negligible (< 3%)
and encapsulation eﬃciency of bacteriophage can reach 100%. The
drop productivity can exceed 10,000 drops/s [245], however, the ﬂow
rate of the dispersed phase is modest (0.01–10 ml h−1/drop generation
unit - DGU). The most common planar DGUs are co-ﬂow drop makers in
which immiscible ﬂuids meet in parallel streams, cross-ﬂow drop ma-
kers or microﬂuidic junctions in which the immiscible ﬂuid streams
meet at an angle to one another, and ﬂow-focusing drop makers in
which there is a geometric element, such as a constriction, that causes
the streams to accelerate, narrowing the inner ﬂuid thread and causing
it to break into drops [243].
Microﬂuidic emulsiﬁcation allows for precise fabrication of struc-
tured multiple emulsions with controlled drop morphology.
Conventional multiple emulsions are composed of numerous drops of
the inner phase dispersed within larger drops of the middle phase,
which itself is dispersed in an outer phase (Fig. 4 a). The middle phase
must be immiscible with both the inner and outer phase. A W1/O/W2
emulsion consists of drops of the inner water phase W1 dispersed within
the oil drops, which are then dispersed in the outer water phase W2.
Bacteriophage typically would be suspended in W1 phase and the oil
phase would contain a suspended or dissolved encapsulating shell
material such as a polymer. Microﬂuidic methods can be used to pro-
duce multiple emulsion drops consisting of a controlled number of
inner drops encapsulated within each large drop (Fig. 4 b) [246]. The
number and content of individual inner drops can be controlled thereby
allowing the loading of bacteriophage to be precisely manipulated
[246,247]. The distinct inner drops can be used to achieve simulta-
neous encapsulation of two or more types of bacteriophage in separate
microenvironments and to control the loading for each of them. Thus
phage cocktails may be individually formulated to overcome the lim-
itations of one formulation having to suit all.
Microﬂuidic methods can be used to prepare multiple emulsion
drops with concentric onion-like shells around the core drop (Fig. 4 c).
Droplets with diﬀerent numbers of shells may be synthesised depending
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Fig. 4. Morphologies of complex drops: (a) Conventional
multiple emulsion drop; (b) multiple emulsion drops generated
in microﬂuidic channels with controlled number of inner drops
[246] and distinct inner drops [247]; (c) drops generated in
microﬂuidic channels with multiple concentric shells [249];
(d) Janus and ternary drops generated in microﬂuidic channels
[250,251].
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of the number of immiscible phases within each drop e.g. double (W1/
O/W2 or O1/W/O2), triple (W1/O2/W3/O4 or O1/W2/O3/W4), quad-
ruple (W1/O2/W3/O4/W5 or O1/W2/O3/W4/O5), and quintuple (W1/
O2/W3/O4/W5/O6 or O1/W2/O3/W4/O5/W6) [248]. High-order mul-
tiple emulsions may be useful in the production of complex capsules for
co-encapsulation and simultaneous or sequential release of several
multi-component actives (Fig. 4 c) [249]. Multiple shells would allow
tailored formulations within a single capsule e.g. an outer acid stable
shell may protect phage from the stomach acidity, an inner burst re-
lease shell for bolus delivery of phage with an innermost sustained
release shell resulting in slow sustained phage release over a signiﬁcant
time period negating the need for repeated phage dosing.
Other approaches might include phage encapsulation in Janus
particles composed of two hemispheres with various physical and
chemical properties (Fig. 4 d). Janus drops typically have two distinct
regions of roughly equal surface area, however, the term has expanded
to include all multi-segment droplet structures with regions of diﬀerent
composition co-existing in asymmetric geometries [250]. Janus parti-
cles may be used to encapsulate bacteriophage in diﬀerent polymers
having diﬀerent in vivo degradation rates to achieve burst release fol-
lowed by controlled sustained release.
6. Conclusions
Implementation of phage therapy necessitates the use of phage
cocktails to overcome the limited host range of an individual phage and
the risk of phage resistant bacterial mutants. High doses of phage need
to be reliably delivered at the site of infection. Repeated frequent
dosing of phage may be impractical hence, encapsulation of phage in
sustained release systems is needed. Bacteriophage susceptibility to
chemical and physical stresses diﬀers among phage families and also
within a family. Careful consideration needs to be given to ensure the
formulation chemistry and processing conditions are suited to phage
making-up the cocktail in order to ensure reproducible retention of high
phage titres and stability during long term storage. Further research is
urgently needed in the ﬁeld of phage formulation and encapsulation to
adequately support any future phage therapy ﬁeld.
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Appendix A. Mathematical model of bacteria/phage interaction
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Here
S, R - concentrations of susceptible and resistant bacteria accordingly [CFU/ml],
P1 - concentration of the phage aﬀecting susceptible bacteria only [PFU/ml],
P2 - concentration of the phage aﬀecting both susceptible and resistant bacteria [PFU/ml],
T - latent period [min]; index ‘T’ indicates the value of the variable T minutes in the past,
g - bacteria growth rate coeﬃcient [min−1],
a - (bacteria/phage) adsorption coeﬃcient [ml min−1 PFU−1],
n - average number of phages adsorbed by an individual bacterium,
b - burst size,
m - probability of bacteria mutation resulting in resistance to phage P1,
d - phage death/removal coeﬃcient [min−1].
For both ﬁgures in the paper the following values were used: g= 0.02 min−1, n= 1, b= 30, m= 10−5, d= 0.02 min−1.
For the results shown in Fig. 1: a= 10−10 ml/min, T= 40 min.
For the results shown in Fig. 2: a= 0.5 ∗ 10−10 ml/min, T= 60 min.
Also, for any given latency period T a discrete distribution in the range 0.76T–1.24T was used instead of the ﬁxed T. It was T for 48% of infected
bacteria, 0.88T for 20%, 1.12T for 20%, 0.76T for 6% and 1.24T for 6% - as the ﬁgure below illustrates for T= 30 min.
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